

MERIDIAN BIOSCIENCE INC  
Form 424B3  
November 12, 2003

Filed pursuant to Rule 424(b)3  
Registration number 333-109139

OFFERING MEMORANDUM

MERIDIAN BIOSCIENCE, INC.  
OFFER TO EXCHANGE

5% CONVERTIBLE SUBORDINATED DEBENTURES DUE 2013

FOR UP TO \$16,000,000 PRINCIPAL AMOUNT OF ITS OUTSTANDING

7% CONVERTIBLE SUBORDINATED DEBENTURES DUE 2006

THE EXCHANGE OFFER WILL EXPIRE AT 12:00 MIDNIGHT, EASTERN TIME,  
ON DECEMBER 11, 2003, UNLESS EXTENDED OR EARLIER TERMINATED

We are offering to exchange up to \$16,000,000 in aggregate principal amount of our 5% Convertible Subordinated Debentures Due 2013 for our outstanding 7% Convertible Subordinated Debentures Due 2006. In this Offering Memorandum, we refer to the 5% Convertible Subordinated Debentures Due 2013 as the new debentures and the 7% Convertible Subordinated Debentures Due 2006 as the existing debentures. We refer to the new debentures and existing debentures collectively as the debentures.

Principal features of the exchange offer include:

- We will issue \$1,000 in principal amount of new debentures in exchange for each \$1,000 in principal amount of existing debentures, up to a maximum of \$16,000,000, that are validly tendered and not withdrawn prior to the expiration date.
- There are \$20,000,000 of existing debentures outstanding. If holders tender more than \$16,000,000 of existing debentures, we will accept existing debentures for exchange as nearly as possible on a pro rata basis, in accordance with the principal amount tendered by each holder. Therefore, you may not be able to exchange all of the debentures which you tender.
- The exchange offer is not conditioned on a minimum amount of existing debentures being validly tendered and not withdrawn.
- Interest accrued since September 1, 2003 on tendered existing debentures that are accepted by us will be paid with the first payment of interest on the new debentures after the date of exchange, March 1, 2004, the same as the existing debentures.
- Tenders may be withdrawn at any time prior to the expiration date of the exchange offer which is 12:00 midnight, Eastern time, on December 11, 2003, unless extended or earlier terminated.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the debentures to be issued in the exchange offer or passed upon the adequacy or accuracy of this Offering Memorandum. Any representation to the contrary is a criminal offense.

Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

THE EXCHANGE AGENT  
FOR THE EXCHANGE OFFER IS:

LASALLE BANK, NATIONAL ASSOCIATION  
135 South LaSalle Street, Suite 1811  
Chicago, IL 60603  
Attention: Corp. Trust Operations  
Phone: (312) 904-2450  
Toll-free: (800) 246-5761

THE INFORMATION AGENT  
FOR THE EXCHANGE OFFER IS:

D.F. KING & CO., INC.  
48 Wall Street  
22nd Floor  
New York, NY 10005  
Banks and Brokerage Firms, Please Call: (212) 269-5550  
All Others Call Toll-free: (888) 887-8878

THE DATE OF THIS OFFERING MEMORANDUM IS NOVEMBER 12, 2003

We are offering to exchange existing debentures for new debentures only in places where offers and sales are permitted.

This Offering Memorandum summarizes various documents and other information. Those summaries are qualified in their entirety by reference to the documents and information to which they relate. In making an investment decision, investors must rely on their own examination of our business and the terms of the exchange offer, including the merits and risks involved. The information contained in this Offering Memorandum is as of the date hereof and neither the delivery of this Offering Memorandum nor the offering, sale or delivery of any new debentures shall create any implication that the information contained herein is correct at any time after the date hereof. The contents of this Offering Memorandum are not to be construed as legal, business or tax advice. Each prospective investor should consult the investor's own attorney, business advisor and tax advisor as to legal, business or tax advice with respect to an investment in the new debentures.

All inquiries relating to the procedures for tendering in the exchange offer should be directed to the exchange agent, at the telephone number or address listed on the front and back cover pages of this Offering Memorandum. Requests for additional copies of this Offering Memorandum, the enclosed Letter of Transmittal or Notice of Guaranteed Delivery, or for copies of the periodic reports filed by us with the SEC and described in this Offering Memorandum may be directed to the information agent, at one of the telephone numbers or the address listed on the front and back cover pages of this Offering Memorandum. You may also obtain additional information from us at the telephone number or address listed in the section of this Offering Memorandum entitled "Incorporation by Reference."

You should not assume that the information contained or incorporated by reference into this Offering Memorandum is accurate as of any date other than the date of the Offering Memorandum or document incorporated by reference, as the case may be.

-----  
TABLE OF CONTENTS  
-----

Summary Term Sheet.....  
Meridian Bioscience, Inc.....  
New Debentures.....

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

Selected Consolidated Financial Data.....	
Pro Forma Financial Information.....	
Risk Factors.....	
Market For Existing Debentures And Common Stock.....	
Use Of Proceeds.....	
The Exchange Offer.....	
Material United States Federal Income Tax Considerations Of The Exchange Offer.....	
Description Of New Debentures.....	
Comparison Of Terms Of Existing Debentures And New Debentures.....	
Description Of Common Stock.....	
Description Of Other Indebtedness.....	
Legal Matters.....	
Independent Auditors.....	
Where You Can Find More Information.....	
Incorporation By Reference.....	

2

Our principal executive offices are located at 3471 River Hills Drive, Cincinnati, Ohio, 45244, and our telephone number is (513) 271-3700. We maintain our corporate website at [www.meridianbioscience.com](http://www.meridianbioscience.com). Information on our website is not part of this Offering Memorandum.

### SUMMARY TERM SHEET

- Why are you making the exchange offer?

If we issue \$16,000,000 of new debentures in exchange for the same amount of existing debentures, we will have reduced subordinated debt by \$4,000,000 and increased senior debt by the same amount, reduced interest charges by approximately \$500,000 per annum, extended the maturity of our subordinated debt by 7 years and reduced the number of shares issuable under convertible debentures from 1,243,000 to 1,103,000.
- What securities are sought in the exchange offer?

We are offering to exchange up to \$16,000,000 of existing debentures for new debentures. As of the date of this Offering Memorandum, \$20,000,000 of existing debentures are outstanding.
- What are you offering in exchange for my existing debentures?

We are offering to issue a new debenture with a principal amount equal to the principal amount of each existing debenture that is properly tendered in the exchange offer and not withdrawn. We will issue up to \$16,000,000 of the new debentures. The new debentures, like our existing debentures, will be subordinated in right of payment to all of our existing and future senior indebtedness (as described in this Offering Memorandum). The new debentures will be of equal rank with the existing debentures that remain outstanding after the exchange offer. See "Description of New Debentures" for more information.
- What are the material differences between the new debentures and the existing debentures?

3

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

The main differences are that the annual interest rate on the new debentures will be 5% while the annual interest rate on the existing debentures is 7%, that the maturity date of the new debentures will be in 2013 while the existing debentures mature in 2006 and that the conversion price on the new debentures will be \$14.50 per share while the current conversion price on the existing debentures is \$16.09 per share. See "Comparison of Terms of Existing Debentures and New Debentures" for more information.

- What are your plans with respect to the other \$4,000,000 of existing debentures?

Assuming that we exchange the maximum of \$16,000,000 in existing debentures for new debentures in the exchange offer, we plan to commence redeeming the unexchanged existing for cash at par plus accrued interest, which may continue over the next 12 months. See "Comparison of Terms of Existing Debentures and New Debentures-Optional Redemption."

If less than \$16,000,000 in existing debentures is exchanged in the exchange offer, we may redeem all or a portion of the unexchanged existing debentures for cash at par plus accrued interest or may keep all or a portion of the remaining existing debentures outstanding until maturity in 2006. We will determine the amount, if any, of unexchanged existing debentures to redeem based on the principal amount of existing debentures remaining outstanding, our available cash on hand and our ability to utilize our bank credit facility while being able to meet our short and long term cash needs. We expect to make this determination within 12 months following expiration of this offer.

- What does your board of directors think of the exchange offer?

Although our board of directors believes that the exchange offer is in our best interests, our board of directors is not making any recommendation regarding whether you should tender your existing debentures in the exchange offer. You must make your own determination as to whether to tender your existing debentures in exchange for new debentures. We urge you to read carefully this Offering Memorandum and the other documents to which we refer you in their entirety, including the discussion of risks and uncertainties affecting our business and the exchange offer set forth in the section of this Offering Memorandum entitled, "Risk Factors."

- How will you select existing debentures for exchange if more than \$16,000,000 in principal amount are tendered?

If more than \$16,000,000 of existing debentures are properly tendered and not withdrawn, we will accept for exchange existing debentures as nearly as possible on a pro rata basis, in accordance with the principal amount of existing debentures tendered by each holder of existing debentures.

- What are the conditions to the exchange offer?

The exchange offer is subject to a number of conditions. If any of the conditions to the exchange offer are not satisfied, we will not be obligated to accept any tendered existing debentures for exchange. However, we reserve the right to waive any of the

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

conditions to the exchange offer. See "Exchange Offer--Conditions to Exchange Offer" for more information.

- Will the accrued interest on my tendered existing debentures be paid?

4

You are not being asked to forego any accrued interest on existing debentures that are tendered in the exchange offer. The interest that has accrued since September 1, 2003 on tendered existing debentures that are accepted by us will be paid with the first payment of interest on the new debentures, which will be March 1, 2004. The interest on tendered existing debentures will accrue to the date that the existing debentures are accepted for exchange in the exchange offer, which is expected to occur on December 12, 2003 if all of the conditions to the exchange offer are satisfied or waived.

- Have the new debentures been registered with the SEC?

We are not required to have an effective registration statement on file with the SEC to register the issuance of the new debentures in the exchange offer because the exchange offer is being extended to you in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act.

- Do you currently have a sufficient number of shares of common stock available for issuance upon conversion of the new debentures?

We currently have a sufficient number of shares of common stock reserved for issuance to allow the conversion of the maximum number of new debentures that could be issued in the exchange offer. We will keep reserved for issuance upon conversion of the new debentures a sufficient number of shares of common stock during the entire term of the new debentures.

- Can I transfer the new debentures and shares of common stock issuable upon the conversion of the new debentures to third parties?

The sale of the existing debentures was registered by us under a registration statement on Form S-3 filed with the SEC. The exchange offer is being extended to you in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act. In accordance with SEC interpretations, the new debentures received by you in the exchange offer will assume the same character as the existing debentures tendered by you. As a result, the new debentures we issue to you in exchange for your existing debentures, and the shares of common stock issuable upon the conversion of the new debentures, will be freely tradable by all holders other than our affiliates.

- Will the new debentures be listed for trading?

The existing debentures are not listed for trading. We do not anticipate that the new debentures will be listed for trading on any exchange or market.

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

- What will be the federal income tax consequences of the exchange offer to the holders of the existing debentures?

The exchange offer will generally not be taxable for U.S. federal income tax purposes to U.S. holders exchanging existing debentures for new debentures. See "Material United States Federal Income Tax Consequences of the Exchange Offer" for more information.

- Will you receive any cash proceeds from the exchange offer?

We will not receive any cash proceeds from the exchange offer.

- How long do I have to decide whether to tender in the exchange offer?

5

You will have until 12:00 midnight, Eastern time, on December 11, 2003 to decide whether to tender your existing debentures in the exchange offer. If you cannot deliver the existing debentures and the other documents required to make a valid tender by that time, you may be able to use the guaranteed delivery procedures, which are described in this Offering Memorandum.

- Can the exchange offer be extended or amended and under what circumstances?

We have retained the right to extend or amend the exchange offer, in our sole discretion, and we expressly reserve the right to do so. During any extension of the exchange offer, all existing debentures previously tendered and not withdrawn will remain subject to the exchange offer. During any period of time in which the exchange offer remains open, you have the right to withdraw previously tendered existing debentures. If the exchange offer expires and we have not agreed to accept your existing debentures for exchange by December 11, 2003, you can withdraw them at any time after that date until we do accept your existing debentures for exchange.

- How will I be notified if the exchange offer is extended?

If we extend the exchange offer, we will issue a press release or another form of public announcement no later than 9:00 a.m., Eastern time, on the next business day after the previously scheduled expiration date of the exchange offer.

- How do I tender existing debentures?

To tender existing debentures, you must deliver your existing debentures, together with a completed Letter of Transmittal and any other documents required by the Letter of Transmittal, to LaSalle Bank, National Association, the exchange agent for the exchange offer, not later than the time the exchange offer expires. If your existing debentures are held in street name (that is, through a broker, dealer or other nominee) the existing debentures can be tendered by your nominee through The Depository Trust Company, also known as DTC. If you cannot provide the exchange agent with all required documents prior to the expiration date of the exchange offer, you may obtain additional time to do

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

so by submitting, prior to the expiration date of the exchange offer, a Notice of Guaranteed Delivery to the exchange agent. You must also guarantee that these items will be received by the exchange agent within three New York Stock Exchange trading days after the date the exchange agent receives your Notice of Guaranteed Delivery. However, for your tender to be valid, the exchange agent must receive the missing items within that three trading day period. See "The Exchange Offer" for more information.

- How long can I withdraw previously tendered existing debentures?

You can withdraw previously tendered existing debentures at any time until the exchange offer has expired. In addition, if we have not agreed to accept your existing debentures for exchange by December 11, 2003, you can withdraw them at any time after that date until we do accept your existing debentures for exchange. See "The Exchange Offer--Withdrawal of Tenders" for more information.

- How do I withdraw previously tendered existing debentures?

To withdraw previously tendered existing debentures, deliver a written notice of withdrawal (or a facsimile of one) to the exchange agent, along with all information required by the

6

notice of withdrawal, during the times when withdrawals are permitted. See "The Exchange Offer--Withdrawal of Tenders" for more information.

- When will I receive new debentures in exchange for my tendered existing debentures?

Subject to the satisfaction or waiver of all conditions to the exchange offer, and assuming we have not previously elected to terminate the exchange offer, we will accept for exchange all existing debentures up to a maximum of \$16,000,000 in principal amount that are properly tendered and not withdrawn prior to the expiration date of the exchange offer. Promptly following this date, new debentures will be delivered in exchange for the same principal amount of existing debentures that are properly tendered and not withdrawn.

- What happens if existing debentures are tendered but not accepted for exchange?

If we decide for any reason not to accept any existing debentures for exchange, we will return the existing debentures to the registered holder at our expense promptly after the expiration or termination of the exchange offer. In the case of existing debentures tendered by book-entry transfer into the exchange agent's account at DTC, DTC will credit any unaccepted or non-exchanged existing debentures to the tendering holder's account at DTC.

- Do I have to tender any of my existing debentures?

No. This offer is purely voluntary. However, assuming that we

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

exchange the maximum of \$16,000,000 in existing debentures for new debentures in the exchange offer, we plan to commence redeeming the unexchanged existing debentures for cash at par plus accrued interest over the next 12 months.

If less than \$16,000,000 in existing debentures is exchanged in the exchange offer, we may redeem all or part of the remaining unexchanged existing debentures for cash at par plus accrued interest or may keep the remaining existing debentures outstanding until maturity in 2006. We will determine the amount, if any, of unexchanged existing debentures to redeem based on our available cash on hand and our ability to utilize our bank credit facility while being able to meet our short and long term cash needs.

- To whom should I direct questions about the exchange offer?

If you have questions regarding the procedures for tendering in the exchange offer or require assistance in tendering your existing debentures, please contact D.F. King & Co, Inc., the information agent for the exchange offer, at the telephone number or address set forth on the front and back cover pages of this Offering Memorandum. If you would like to obtain additional copies of this Offering Memorandum, the enclosed Letter of Transmittal or copies of any of our SEC reports described in this Offering Memorandum, contact the exchange agent, at one of the telephone numbers or the address set forth on the back cover page of this Offering Memorandum. You can also contact us for additional information at the address and telephone number listed below under "Incorporation by Reference."

7

### MERIDIAN BIOSCIENCE, INC.

We are a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative, disposable diagnostic test kits and related diagnostic products used for the rapid diagnosis of infectious diseases. We also offer biopharmaceutical capabilities through our cGMP protein production laboratory at our Viral Antigens subsidiary.

Our diagnostics products provide accuracy, simplicity and speed, and enable early diagnosis and treatment of common medical conditions such as gastrointestinal, viral, and respiratory infections. All of our diagnostics products are used in procedures performed in vitro (outside the body) and enhance patient well-being while reducing total outcome costs of healthcare.

In addition to the diagnostic business, we are expanding further into the area of life science. Through recent acquisitions, we have the technical expertise to enable research efforts of genomics scientists in drug and vaccine development. The expansion into life science prompted our decision to change our official name to Meridian Bioscience, Inc. in fiscal 2001.

Our diagnostic product development strategy is to combine existing technologies with new product designs, both through internal or joint product development, and through product acquisitions, licensing or supply arrangements. Internal and joint product development activities focus on the development or enhancement of immunodiagnostic technologies and applications to simplify, accelerate or increase the accuracy of diagnoses of certain infectious diseases.



## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

Since 1990, we have acquired or obtained rights to distribute numerous products and technologies.

We utilize our resources to serve each of the strategic domestic and international medical markets it has targeted: hospital networks and clinical and hospital laboratories; outpatient clinics, and health maintenance organizations (HMOs); and new markets, including veterinary laboratories and water treatment facilities. We market over 200 products representing four major disease states through a direct sales force in the United States, Italy, France, Belgium and the Netherlands, supplemented by a network of national and international distributors.

A more detailed description of our business is found in the Form 10-K for fiscal 2002 and our other SEC filings, all of which are incorporated by referenced.

Our principal executive offices are located at 3471 River Hills Drive, Cincinnati, Ohio, 45244, and our telephone number is (513) 271-3700. We maintain our corporate website at [www.meridianbioscience.com](http://www.meridianbioscience.com). Information on our website is not part of this Offering Memorandum.

The following persons are the directors and/or officers and/or controlling persons of Meridian:

William J. Motto	Chairman of the Board of Directors, Chief Executive Officer
John A. Kraeutler	President, Chief Operating Officer and Director
Antonio A. Interno	Senior Vice President
Richard L. Eberly	Executive Vice President
Kenneth J. Kozak	Vice President, Research and Development
Melissa A. Lueke	Vice President, Chief Financial Officer and Secretary
Susan A. Rolih	Vice President of Regulatory Affairs & Quality Services
Lawrence J. Baldini	Vice President of Operations
James A. Buzard	Director
Gary P. Kreider	Director
Robert J. Ready	Director

8

David C. Phillips	Director
-------------------	----------

The address of each person listed above is c/o Meridian Bioscience, Inc., 3471 River Hills Drive, Cincinnati, Ohio 45244, and each such person's telephone number is (513) 271-3700.

William J. Motto beneficially owns \$50,000 principal amount of the existing debentures. Gary P. Kreider beneficially owns \$26,000 principal amount of existing debentures. They both plan to tender all of their existing debentures to the Exchange Offer.

9

# Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

## NEW DEBENTURES

The following summary contains basic information about the debentures. See also the section of this document entitled "Description of Debentures."

Maturity Date.....	The new debentures will mature on September 1, 2013.
Interest Payment Dates.....	Each March 1 and September 1, beginning September 1, 2004.
Conversion.....	The new debentures are convertible at the option of the holder, in whole or in part, at any time prior to maturity, unless previously restricted by the terms of the shares of common stock at \$14.50 per share, subject to adjustment under certain conditions.
Optional Redemption.....	Redeemable at our option, at any time beginning September 1, 2004, in whole or in part, at the redemption prices set forth in this Offering Memorandum, plus accrued interest.
Ranking.....	The new debentures will be subordinated to all existing and future senior indebtedness (as defined in this Offering Memorandum). There is no assurance that the amount of senior indebtedness that we will incur will be less than the amount of the new debentures.
Absence of Market for the Debentures.....	The new debentures are a new issue of securities and do not have an established trading market. We currently have no intention to apply to list the new debentures on any securities exchange or to seek their admission to trading on any automated quotation system. As a result, we cannot provide any assurance as to the liquidity of any market for the new debentures.
Registration.....	The sale of the existing debentures was completed under a registration statement on Form S-3 filed with the SEC. The exchange offer is being made in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act. In accordance with SEC interpretations, the new debentures you in the exchange offer will assume the same status as the existing debentures tendered by you. As a result, the new debentures we issue to you in exchange for your existing debentures, and the new debentures issuable upon the conversion of the new debentures, should be freely tradable by you.

## SELECTED CONSOLIDATED FINANCIAL DATA

The selected consolidated financial data set forth below is derived

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

from our unaudited consolidated financial statements for the nine months ended June 30, 2003 and 2002 and from our audited financial statements for the fiscal years ended September 30, 2002, 2001, 2000, 1999 and 1998. The unaudited consolidated interim results, in the opinion of management, reflect all adjustments (consisting solely of normal recurring adjustments), which are necessary to present fairly the results for the unaudited interim periods. The unaudited interim results for the nine months ended June 30, 2003 are not necessarily indicative of the results that may be expected for the year ending September 30, 2003. The following selected consolidated financial data should be read in conjunction with the more detailed information contained in the consolidated financial statements and notes thereto and "Management's Discussion and Analysis of Financial Condition and Results of Operations" incorporated by reference in this Offering Memorandum.

	NINE MONTHS ENDED JUNE 30,		FISCAL YEAR ENDED SEP		
	2003	2002	2002 (a)	2001 (b)	2000 (c)
<b>INCOME STATEMENT INFORMATION</b>					
Net Sales	\$48,709	\$43,545	\$59,104	\$56,527	\$57,096
Gross profit	28,353	25,242	34,598	26,706	35,446
Operating income (loss)	9,614	8,081	9,994	(12,507)	9,354
Net earnings (loss)	5,169	4,168	5,031	(10,275)	7,111
Basic earnings (loss) per share	\$ 0.35	\$ 0.29	\$ 0.34	\$ (0.70)	\$ 0.49
Diluted earnings (loss) per share	\$ 0.35	\$ 0.28	\$ 0.34	\$ (0.70)	\$ 0.49
Cash dividends declared per share	\$ 0.25	\$ 0.21	\$ 0.28	\$ 0.26	\$ 0.23
Book value per share	\$ 1.81	\$ 1.67	\$ 1.67	\$ 1.57	\$ 2.51
Ratio of earnings to fixed charges	6.94	5.02	4.82	(e)	4.04

	AS OF JUNE 30,		AS OF SEPTEMBER		
	2003	2002	2002	2001	2000
<b>BALANCE SHEET INFORMATION</b>					
Current assets	\$31,809	\$31,899	\$30,375	\$32,502	\$40,798
Current liabilities	14,094	14,976	15,249	16,368	16,619
Total assets	65,073	65,366	65,095	65,982	84,717
Long-term debt obligations	22,436	23,886	23,626	24,349	27,159
Shareholders' equity	26,618	24,439	24,381	22,944	36,611

- (a) Includes after-tax costs of \$0.8 million or \$0.05 per diluted share for abandoned acquisition.
- (b) Includes after-tax costs of \$9.8 million or \$0.67 per diluted share, \$1.1 million or \$0.08 per diluted share, and \$0.8 million or \$0.05 per diluted share for FDA matters, European restructuring and acquired in-process research and development, respectively.
- (c) Includes tax benefits of \$4.6 million or \$0.32 per diluted share, and after-tax costs of \$2.1 million or \$0.14 per diluted share, related to European restructuring.
- (d) Includes after-tax costs of \$2.2 million or \$0.15 per diluted share, and \$1.5 million or \$0.10 per diluted share for merger integration and acquired in-process research and development, respectively.
- (e) For the fiscal year ended September 30, 2001, earnings were inadequate to

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

cover fixed charges. The deficiency of earnings needed to attain a ratio of 1.0 to 1.0 was \$14.9 million on a pre-tax basis.

11

### PRO FORMA FINANCIAL INFORMATION

We have evaluated the effects of the exchange and redemption transactions on our historical operating results. We believe that such transactions do not have a significant effect on the amount of earnings or earnings per share reported for the nine-month period ended June 30, 2003 or the fiscal year ended September 30, 2002. We also believe that such transactions do not have a significant effect on the amount of book value per share or total liabilities outstanding at June 30, 2003.

The exchange and redemption transactions do favorably affect the ratio of earnings to fixed charges for the nine-month period ended June 30, 2003 and the fiscal year ended September 30, 2002, reported under "Selected Consolidated Financial Data" above. The ratio of earnings to fixed charges reported on a pro forma basis, after giving effect to the exchange and redemption transactions is as follows.

#### NINE-MONTH PERIOD ENDED JUNE 30, 2003

Historical - 6.94  
Pro forma - 10.12

#### FISCAL YEAR ENDED SEPTEMBER 30, 2002

Historical - 4.82  
Pro forma - 6.51

The ratio of earnings to fixed charges on a pro forma basis reflects the favorable effects of the reduction in interest costs. The interest rate on the existing debentures is fixed at 7%. The weighted average interest rates on a pro forma basis are 4.48% and 4.68% for the nine-month period ended June 30, 2003 and the fiscal year ended September 30, 2002, respectively.

### RISK FACTORS

You should carefully consider the risk factors described below and all other information contained in this Offering Memorandum, as well as the other information we include or incorporate by reference in this Offering Memorandum and the additional information in the reports that we file with the SEC, before deciding to exchange your existing debentures.

#### RISKS RELATED TO US

WE MAY BE UNABLE TO INTEGRATE SUCCESSFULLY OPERATIONS OR TO ACHIEVE EXPECTED COST SAVINGS FROM ACQUISITIONS WE MAKE.

One of our main growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses successfully integrated into our operations.

Although additional acquisitions of companies and product lines may enhance the opportunity to increase net earnings over time, such acquisitions

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

could result in greater administrative burdens, increased exposure to the uncertainties inherent in marketing new products, financial risks of additional operating costs and additional interest costs. The principal benefits expected to result from any acquisitions made by us will not be achieved fully unless the operations of the acquired entities are successfully integrated with our operations. There can be no assurance that we will be able to conclude any acquisition in the future on favorable terms and that it will be successfully integrated into our operations.

12

WE MAY BE UNABLE TO DEVELOP NEW PRODUCTS OR ACQUIRE PRODUCTS ON FAVORABLE TERMS.

The diagnostic and life science industries are characterized by ongoing technological developments and changing customer requirements. As a result, our success and continued growth depend, in part, on our ability in a timely manner to develop or acquire rights to, and successfully introduce into the marketplace, enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by our competition. There can be no assurance that we will be successful in developing or acquiring such rights to products on a timely basis or that such products will adequately address the changing needs of the marketplace.

WE ARE DEPENDENT ON INTERNATIONAL SALES, AND OUR FINANCIAL RESULTS MAY BE ADVERSELY IMPACTED BY FOREIGN CURRENCY, REGULATORY OR OTHER DEVELOPMENTS AFFECTING INTERNATIONAL MARKETS.

Approximately 30% of our net sales for fiscal 2002 and approximately 35% through the nine months ended June 30, 2003 were attributable to international sales. Approximately half of our international sales have been made in U.S. dollars while the other half is made primarily in Euros. We are subject to the risks associated with fluctuations in currency exchange rates. We are also subject to other risks associated with international operations, including tariff regulations, requirements for export licenses and medical licensing and approval requirements.

CHANGING MARKET CONDITIONS COULD ADVERSELY IMPACT OUR FINANCIAL RESULTS.

Changes in the healthcare delivery system have resulted in major consolidation among reference laboratories and in the formation of multi-hospital alliances, reducing the number of institutional customers for diagnostic test products. There can be no assurance that we will be able to enter into and/or sustain contractual or other marketing or distribution arrangements on a satisfactory commercial basis with these institutional customers.

INTENSE COMPETITION COULD ADVERSELY AFFECT OUR PROFITABILITY.

The market for our products is characterized by substantial competition and rapid change. Hundreds of companies in the United States supply immunodiagnostic tests and purified reagents. These companies range from multinational healthcare entities of which immunodiagnostics is one line of business, to small start-up companies. Many of our competitors have significantly greater financial, technical, manufacturing and marketing resources than we do.

WE RELY UPON KEY DISTRIBUTORS TO RESELL OUR PRODUCTS, AND IF WE ARE NOT ABLE TO RETAIN THESE KEY DISTRIBUTORS, OUR REVENUES COULD BE NEGATIVELY AFFECTED.

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

Our sales to two distributors were approximately \$15.0 million, or approximately 25% of total sales, in fiscal 2002. These distributors resell our products and other laboratory products to end-user customers. The loss of either of these distributors could negatively impact our sales and results of operations.

WE ARE SUBJECT TO COMPREHENSIVE REGULATION, AND OUR ABILITY TO EARN PROFITS MAY BE RESTRICTED BY THESE REGULATIONS.

There is no assurance that we will be able to obtain the necessary clearances or timely clearances to market future products. Costs and difficulties in complying with laws and regulations administered by the FDA can result in unanticipated expenses and delays and interruptions to the sale of new and existing products.

13

Third party payors (including state and federal governments) are increasingly concerned about escalating health care costs and can indirectly affect the pricing or the relative attractiveness of our products by regulating the maximum amount of reimbursement they will provide for diagnostic testing services. If reimbursement amounts for diagnostic testing services are decreased in the future, such decreases may reduce the amount that will be reimbursed to hospitals or physicians for such services and consequently could reduce the price we can charge for our products.

In recent years, the federal government has been examining the nation's health care system from numerous standpoints, including the cost of and access to health care and health insurance. Proposals impacting the health care system are constantly under consideration and could be adopted at any time. It is unclear what effect the enactment of such proposals would have on us.

OUR OFFICERS, DIRECTORS AND EXISTING SHAREHOLDERS EXERCISE SUBSTANTIAL CONTROL OVER OUR AFFAIRS.

Our officers, directors, principal shareholders and their affiliates beneficially own approximately 30% of our outstanding common stock, all of which shares are eligible for sale under Securities and Exchange Commission Rule 144 under the Securities Act of 1933. As a result, these shareholders, if they were to act in concert, would have the ability to influence significantly most matters requiring approval by our shareholders, including the election of a majority of the directors. In addition, our board of directors has the authority to issue up to 1,000,000 shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions, including voting rights, of such shares without any future vote or action by the shareholders. The voting power of these principal shareholders, officers and directors or the issuance of preferred stock under certain circumstances could have the effect of delaying or preventing a change in control of us. Ohio corporation law contains provisions that may discourage takeover bids for us that have not been negotiated with the board of directors. Such provisions could limit the price that investors might be willing to pay in the future for shares of the common stock. In addition, sales of substantial amounts of such shares in the public market could adversely affect the market price of the common stock and our ability to raise additional capital at a price favorable to us. See "Description of Common Stock."

### RISKS RELATED TO THE NEW DEBENTURES

WE DO NOT EXPECT THAT THERE WILL BE A PUBLIC MARKET FOR OUR NEW DEBENTURES.

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

The existing debentures have a limited trading market. No assurance can be given that an active market for the new debentures will develop or, if developed, will continue. If no active market develops, it may be difficult to resell your debentures.

THE NEW DEBENTURES WILL BE SUBORDINATED TO OUR SENIOR INDEBTEDNESS.

The new debentures will be subordinated to all existing and future senior indebtedness, as this term is defined in the new debentures, but will rank equally with the existing debentures that remain outstanding after the exchange offer. As of September 30, 2003, we had approximately \$2.8 million of indebtedness outstanding that will rank senior to the new debentures. In addition, because some of our operations are conducted through subsidiaries, claims of holders of indebtedness of such subsidiaries, as well as claims of regulators and creditors of such subsidiaries, will have priority with respect to the assets and earnings of such subsidiaries over the claims of the holders of the new debentures. The indenture for the new indentures will not limit the amount of senior indebtedness or other indebtedness that we or any of our subsidiaries can create, incur, assume or guarantee.

14

THE NEW DEBENTURES INITIALLY MAY BE CONVERTED INTO COMMON STOCK AT A PRICE OF \$14.50 PER SHARE. ON NOVEMBER 10, 2003, THE CLOSING PRICE PER SHARE OF OUR COMMON STOCK ON THE NASDAQ WAS \$10.00.

If the market price for our common stock remains lower than the conversion price for the new debentures, the conversion of our new debentures may not be practicable or profitable because you would be paying more for our common stock than the market price for such shares.

IF YOU HAVE CLAIMS AGAINST US RESULTING FROM YOUR ACQUISITION OR OWNERSHIP OF EXISTING DEBENTURES, YOU WILL GIVE UP THOSE CLAIMS IF YOU EXCHANGE YOUR EXISTING DEBENTURES.

By tendering your existing debentures in the exchange offer, you will be deemed to have waived any and all rights to receive any payments, including without limitation interest payments beyond the date of exchange, and you agree that our obligations to you under the new debenture indentures and new debentures will supersede and replace in their entirety our obligations to you under the existing debenture indenture and existing debentures. In addition, holders who do not tender their existing debentures for exchange and former holders who have already sold their existing debentures will continue to have the right to assert against us their rights under the existing debentures.

THE INDENTURE GOVERNING THE NEW DEBENTURES CONTAINS NO FINANCIAL COVENANTS.

The indenture, like the indenture governing the existing debentures, does not contain any financial performance covenants. Consequently, we are not required under the indenture to meet any financial tests such as those that measure our working capital, interest coverage, fixed charge coverage or net worth in order to maintain compliance with the terms of the indenture.

OUR BANK CREDIT AGREEMENT IMPOSES RESTRICTIONS WITH RESPECT TO US.

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

Our bank credit agreement contains a number of financial covenants that require us to meet certain financial ratios and tests. If we fail to comply with the obligations in the credit agreement, it could result in an event of default under the credit agreement. If an event of default is not cured or waived, it could result in acceleration of the indebtedness under our credit agreement and under other instruments, like the indentures for the debentures, that may contain cross-acceleration or cross-default provisions, any of which could have a material adverse effect on our business.

### MARKET FOR EXISTING DEBENTURES AND COMMON STOCK

As of November 10, 2003, there were approximately 3,000 beneficial owners of existing debentures. The existing debentures are not traded on any exchange or over-the-counter market, and we do not have a comprehensive trading history for the existing debentures.

Our common stock is traded on the Nasdaq National Market under the symbol "VIVO." The following table sets forth, for the periods indicated, the high and low sales prices per share of common stock as reported on Nasdaq and the dividends paid per share of common stock during such period.

	HIGH -----	LOW -----
FISCAL YEAR ENDED SEPTEMBER 30, 2002		
First Quarter.....	\$ 6.690	\$ 4.3
Second Quarter.....	7.830	5.7
Third Quarter.....	7.600	5.8
Fourth Quarter.....	7.000	4.5
FISCAL YEAR ENDED SEPTEMBER 30, 2003		
First Quarter.....	\$ 7.590	\$ 5.410
Second Quarter.....	8.740	6.520
Third Quarter.....	10.500	7.390
Fourth Quarter.....	11.440	8.750
FISCAL YEAR ENDED SEPTEMBER 30, 2004		
First Quarter (through November 10, 2003).....	\$ 10.510	\$ 9.760

15

On November 10, 2003, the closing price per share of our common stock on Nasdaq was \$10.00. As of November 10, 2003, we had approximately 800 shareholders of record and approximately 5,000 beneficial holders of our common stock.

### USE OF PROCEEDS

We will not receive any proceeds from the issuance of the new debentures in the exchange offer.

### RATIO OF EARNINGS TO FIXED CHARGES

The following table sets forth the our ratios of earnings to fixed



Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

charges for the periods indicated.

----- Nine Months Ended -----		----- Year Ended September 30, -----			
June 30,					
----- 2003 -----	----- 2002 -----	----- 2002 -----	----- 2001 -----	----- 2000 -----	----- 1 -----
6.94	5.02	4.82	(1)	4.04	3

(1) For the year ended September 30, 2001, earnings were inadequate to cover fixed charges by \$14,906 on a pre-tax basis.

THE EXCHANGE OFFER

On September 27, 1996, we completed the sale of \$20,000,000 of the existing debentures. The existing debentures were issued under an indenture dated as of September 1, 1996, between us and U.S. Bank, N.A. (formerly known as Star Bank, N.A.), as the trustee. As of the date of this Offering Memorandum, \$20,000,000 in principal amount of the existing debentures are outstanding.

The sale of the existing debentures was registered by us under a registration statement on Form S-3 filed with the SEC. The exchange offer is being extended to you in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act. In accordance with SEC interpretations, the new debentures received by you in the exchange offer will assume the same character as the existing debentures tendered by you. As a result, the new debentures we issue to you in exchange for your existing debentures, and the common stock issuable upon the conversion of the new debentures, will be freely tradable by all holders other than our affiliates.

TERMS OF THE EXCHANGE OFFER; PERIOD FOR TENDERING EXISTING DEBENTURES

This Offering Memorandum and the enclosed Letter of Transmittal constitute an offer to exchange for each existing debenture a new debenture of a principal amount equal to the principal amount of such existing debenture, subject to the terms and conditions described in this Offering Memorandum. This exchange offer is being extended to all holders of the existing debentures. This Offering Memorandum and the enclosed Letter of Transmittal are first

being sent on or about the date of this Offering Memorandum, to all holders of existing debentures known to us. Subject to the conditions listed below, and assuming we have not previously elected to terminate the exchange offer, we will accept for exchange up to \$16,000,000 in principal amount of existing debentures which are properly tendered on or prior to the expiration date of the exchange offer and not withdrawn. The exchange offer will expire at 12:00 midnight, Eastern time, on December 11, 2003. In our sole discretion, we may extend the period of time during which the exchange offer is open.

We will exchange new debentures in the exchange offer for up to \$16,000,000 in principal amount of existing debentures that are properly tendered and not withdrawn prior to the expiration date of the exchange offer.

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

If more than \$16,000,000 in principal amount of the existing debentures are tendered in the exchange offer, we will accept for exchange existing debentures as nearly as possible on a pro rata basis, in accordance with the principal amount of existing debentures tendered by each holder of existing debentures.

The exchange offer is subject to a number of other conditions described below in the section entitled, "Conditions to the Exchange Offer." Subject to applicable securities laws and the terms set forth in this Offering Memorandum, we reserve the right to waive any and all conditions to the exchange offer, to extend the exchange offer, to terminate the exchange offer and otherwise to amend the exchange offer in any respect.

We expressly reserve the right, at any time and from time to time, to extend the period of time during which the exchange offer is open, and thereby delay acceptance for exchange of any existing debentures. If we elect to extend the period of time during which the exchange offer is open, we will give you oral or written notice of the extension and delay, as described below. During any extension of the exchange offer, all existing debentures previously tendered and not withdrawn will remain subject to the exchange offer and may be accepted for exchange by us upon the expiration of the exchange offer. In the case of an extension, we will issue a press release or other public announcement no later than 9:00 a.m., Eastern time, on the next business day after the previously scheduled expiration date of the exchange offer.

We expressly reserve the right to amend or terminate the exchange offer and not to accept for exchange any existing debentures not previously accepted for exchange if any of the conditions to the exchange offer have not been satisfied or for any other reason within our sole and absolute discretion. We will give you prompt notice of any amendment, termination or non-acceptance.

### PAYMENT OF ACCRUED INTEREST ON THE EXISTING DEBENTURES THAT ARE TENDERED IN THE EXCHANGE OFFER

You are not being asked to forego any accrued interest on existing debentures that are tendered in the exchange offer. The interest that has accrued since September 1, 2003 on tendered existing debentures that are accepted by us will be paid with the first payment of interest on the new debentures after the exchange. The interest on tendered existing debentures will accrue to the date that the existing debentures are accepted for exchange in the exchange offer, which is expected to occur on March 1, 2004 if all of the conditions to the exchange offer are satisfied or waived.

### RELEASE OF LEGAL CLAIMS BY TENDERING EXISTING DEBENTURE HOLDERS

By tendering your existing debentures in the exchange offer, you will be deemed to have released and waived any and all claims or causes of action of any kind whatsoever, whether known or unknown, that, directly or indirectly, arise out of, are based upon or are in any manner connected with your ownership or acquisition of the existing debentures, including any related transaction, event,

circumstance, action, failure to act or occurrence of any sort or type, whether known or unknown, including without limitation any approval or acceptance given or denied, which occurred, existed, was taken, permitted or begun prior to the date of such release, in each case, that you, your successors and your assigns have or may have had against us or our subsidiaries, affiliates or shareholders, or our directors, officers, employees, attorneys, accountants, advisors, agents

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

or representatives, in each case whether current or former, or those of our subsidiaries, affiliates or shareholders, whether those claims arise under federal or state securities laws or otherwise.

### CONDITIONS TO THE EXCHANGE OFFER

The exchange offer is subject to the conditions described below.

Notwithstanding any other provision of the exchange offer, we will not be required to accept any existing debentures for exchange or to issue any new debentures in exchange for existing debentures, and we may terminate or amend the exchange offer if, at any time before expiration of this offer, any of the following events occurs:

- the exchange offer is determined to violate any applicable law or any applicable interpretation of the staff of the SEC;
- an action or proceeding is pending or threatened in any court or by any governmental agency or third party that might materially impair our ability to proceed with the exchange offer or materially and adversely affect our business;
- any material adverse development occurs in our business operations;
- we do not receive any governmental approval we deem necessary for the completion of the exchange offer; or
- the indenture for the new debentures has not been qualified under the Trust Indenture Act of 1939.

These conditions are for our benefit only and we may assert them regardless of the circumstances giving rise to any condition. We may also waive any condition in whole or in part at any time in our sole discretion. Our failure at any time to exercise any of the foregoing rights will not constitute a waiver of that right and each right is an ongoing right that we may assert at any time.

We are required under the Trust Indenture Act of 1939 to qualify the indenture pursuant to which the new debentures will be issued. On or about the date of this Offering Memorandum, we will apply to have the indenture so qualified. We will not accept any existing debentures for exchange or issue any new debentures in exchange for existing debentures, if at the time a stop order is threatened or in effect which relates to the qualification of the indenture for the new debentures under the Trust Indenture Act of 1939.

### PROCEDURES FOR TENDERING EXISTING DEBENTURES

When you tender your existing debentures, and we accept the existing debentures for exchange, this will constitute a binding agreement between you and us, subject to the terms and conditions set forth

18

in this Offering Memorandum and the enclosed Letter of Transmittal. You must do one of the following on or prior to the expiration date of the exchange offer to participate in the exchange offer:

- if you hold existing debentures in certificated form, tender your existing debentures by sending your existing debentures, in proper form for transfer, a properly completed and duly

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

executed Letter of Transmittal, with any required signature guarantees, and all other documents required by the Letter of Transmittal, to the exchange agent, at the address set forth on the back cover page of this Offering Memorandum;

- if you hold existing debentures in "street name," tender your existing debentures by using the book-entry procedures described below in the section entitled "Book-Entry Transfer" and transmitting a properly completed and duly executed Letter of Transmittal, with any required signature guarantees, or an "agent's message" instead of the Letter of Transmittal, to the exchange agent; or
- if your existing debentures are not immediately available, time will not permit your existing debentures or other required documents to reach the exchange agent before the expiration date of the exchange offer, or the procedure for book-entry transfer cannot be completed before the expiration date of the exchange offer, you may tender your existing debentures by following the guaranteed delivery procedures described below in the section entitled "Guaranteed Delivery Procedures."

In order for a book-entry transfer to constitute a valid tender of your existing debentures, the exchange agent must receive a confirmation of book-entry transfer of your existing debentures into its account at The Depository Trust Company, also known as DTC, prior to the expiration date of the exchange offer. The term "agent's message" means a message, transmitted by DTC and received by the exchange agent and forming a part of the book-entry confirmation, which states that DTC has received an express acknowledgment from you that you have received and have agreed to be bound by the Letter of Transmittal. If you use this procedure, we will be able to enforce the Letter of Transmittal against you.

The method of delivery of existing debentures, Letters of Transmittal, "agent's messages" and all other required documents is at your election. If you deliver your existing debentures by mail, we recommend registered mail, properly insured, with return receipt requested. In all cases, you should allow sufficient time to assure timely delivery. Please send all existing debentures, Letters of Transmittal and "agent's messages" to the exchange agent, at the address set forth on the back cover page of this Offering Memorandum. Please do not send these materials to us.

Signatures on a Letter of Transmittal or a notice of withdrawal, as the case may be, must be guaranteed by an "eligible guarantor institution" unless you are either:

- a registered existing debenture holder and have not completed the box entitled "Special Payment/Issuance Instructions" or "Special Delivery Instructions" on the Letter of Transmittal; or
- you are exchanging existing debentures for the account of an "eligible guarantor institution."

An "eligible guarantor institution" means:

- Banks, as defined in Section 3(a) of the Federal Deposit Insurance Act of 1950, as amended (the "Federal Deposit Insurance Act");

- Brokers, dealers, municipal securities dealers, municipal securities brokers, government securities dealers and government securities brokers, as defined in the Securities Exchange Act of 1934, as amended (the "Exchange Act");
- Credit unions, as defined in Section 19B(1)(A) of the Federal Reserve Act of 1913, as amended;
- National securities exchanges, registered securities associations and clearing agencies, as these terms are defined in the Exchange Act; and
- Savings associations, as defined in Section 3(b) of the Federal Deposit Insurance Act.

When the Letter of Transmittal is signed by the registered holder of the existing debentures, no endorsement of certificates or separate bond powers are required unless new debentures are to be issued in the name of a person other than the registered holder. Signatures on certificates or bond powers must be guaranteed by an "eligible guarantor institution." The term "registered holder" includes, for this purpose, any participant in DTC's system whose name appears on a security position listing as an owner of existing debentures. If you plan to sign the Letter of Transmittal but you are not the registered holder of the existing debentures, you must have the existing debentures signed by the registered holder of the existing debentures and that signature must be guaranteed by an "eligible guarantor institution." You may also send a separate instrument of transfer or exchange signed by the registered holder and guaranteed by an "eligible guarantor institution," but that instrument must be in a form satisfactory to us in our sole discretion.

All questions as to the validity, form, eligibility, time of receipt and acceptance of existing debentures tendered for exchange will be determined by us in our sole discretion. Our determination will be final and binding. We reserve the absolute right to reject any and all tenders of existing debentures improperly tendered or not to accept any existing debentures, the acceptance of which might be unlawful as determined by us. We also reserve the absolute right to waive any defects or irregularities or conditions of the exchange offer as to any existing debentures either before or after the expiration date of the exchange offer, including the right to waive the ineligibility of any holder who seeks to tender existing debentures in the exchange offer. Our interpretation of the terms and conditions of the exchange offer as to any particular existing debentures either before or after the expiration date of the exchange offer, including the terms and conditions of the Letter of Transmittal and the accompanying instructions, will be final and binding. Unless waived, any defects or irregularities in connection with tenders of existing debentures for exchange must be cured within a reasonable period of time, as determined by us. None of us, the exchange agent or any other person has any duty to give notification of any defect or irregularity with respect to any tender of existing debentures for exchange, nor will any of us, the exchange agent or any other person have any liability for failure to give such notification.

If you are a trustee, executor, administrator, guardian, attorney-in-fact, officer of a corporation, or act in a similar fiduciary or representative capacity, and wish to sign the Letter of Transmittal or any existing debentures or bond powers, you must indicate your status when signing. If you are acting in any of these capacities, you must submit proper evidence satisfactory to us of your authority to so act unless we waive this requirement.

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

### ACCEPTANCE OF EXISTING DEBENTURES FOR EXCHANGE; DELIVERY OF NEW DEBENTURES

Upon satisfaction or waiver of all of the conditions to the exchange offer, and assuming we have not previously elected to terminate the exchange offer, we will accept, promptly after the expiration date of the exchange offer, existing debentures up to a maximum of \$16,000,000 in principal amount that are properly tendered and not withdrawn and will issue

20

the new debentures promptly after acceptance of the existing debentures. For purposes of the exchange offer, we will be deemed to have accepted properly tendered existing debentures for exchange when, as and if we have given oral or written notice of acceptance to the exchange agent, with written confirmation of any oral notice to be given promptly after any oral notice.

For the principal amount of each existing debenture accepted for exchange in the exchange offer, the tendering holder will receive a new debenture of a principal amount equal to that of the principal amount of the existing debenture accepted for exchange. If only a pro rata portion of an existing debenture is accepted for exchange, the holder will be issued an existing debenture for the unaccepted principal amount of the original existing debenture tendered for exchange.

In all cases, the issuance of new debentures in exchange for existing debentures will be made only after the exchange agent timely receives either all physically tendered existing debentures, in proper form for transfer, or a book-entry confirmation of transfer of the existing debentures into the exchange agent's account at DTC, as the case may be, a properly completed and duly executed Letter of Transmittal, with any required signature guarantees, and all other required documents or, in the case of a book-entry confirmation, a properly completed and duly executed Letter of Transmittal, with any required signature guarantees, or an "agent's message" instead of the Letter of Transmittal.

If for any reason we do not accept any tendered existing debentures or if existing debentures are submitted for a greater principal amount than the holder desires to exchange or we accept due to proration, we will return the unaccepted or non-exchanged existing debentures, in the appropriate principal amount, without expense to the registered tendering holder. In the case of existing debentures tendered by book-entry transfer into the exchange agent's account at DTC by using the book-entry procedures described below, the unaccepted or non-exchanged existing debentures will be credited in the appropriate principal amount to the tendering holder's account at DTC. Any existing debentures to be returned to the holder will be returned promptly after the expiration or termination of the exchange offer.

### BOOK-ENTRY TRANSFER

Within two business days after the date of this Offering Memorandum, the exchange agent will make a request to establish an account at DTC for the existing debentures tendered in the exchange offer. Once established, any financial institution that is a participant in DTC's system may make book-entry delivery of existing debentures by causing DTC to transfer the existing debentures into the exchange agent's account at DTC in accordance with DTC's procedures for transfer. Although delivery of the existing debentures may be effected through book-entry transfer at DTC, the Letter of Transmittal or facsimile of the Letter of Transmittal, with any required signature guarantees, or an "agent's message" instead of the Letter of Transmittal, and any other required documents, must be transmitted to and received by the exchange agent on or prior to the expiration date of the exchange offer. In addition, the exchange

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

agent must receive book-entry confirmation of transfer of the existing debentures into the exchange agent's account at DTC prior to the expiration date of the exchange offer. If you cannot comply with these procedures, you may be able to use the guaranteed delivery procedures described below.

### GUARANTEED DELIVERY PROCEDURES

If you are a registered holder of existing debentures and wish to tender your existing debentures, but your existing debentures are not immediately available, time will not permit your existing debentures or other required documents to reach the exchange agent before the expiration date of the exchange offer, or the procedure for book-entry transfer cannot be completed before the expiration date of the exchange offer, you may effect a tender of your existing debentures if:

21

- the tender is made through an "eligible guarantor institution" (as defined above under "Procedures for Tendering existing debentures");
- prior to the expiration date of the exchange offer, the exchange agent receives from an "eligible guarantor institution" a properly completed and duly executed Notice of Guaranteed Delivery, substantially in the form we have provided, setting forth your name and address, and the amount of existing debentures you are tendering and stating that the tender is being made by Notice of Guaranteed Delivery (these documents may be sent by overnight courier, registered or certified mail or facsimile transmission);
- you guarantee that within three NYSE trading days after the date of execution of the Notice of Guaranteed Delivery, all physically tendered existing debentures, in proper form for transfer, or a book-entry confirmation of transfer of the existing debentures into the exchange agent's account at DTC, a properly completed and duly executed Letter of Transmittal, with any required signature guarantees, or an "agent's message" that forms a part of the book-entry confirmation, and any other documents required by the Letter of Transmittal, will be deposited by the "eligible guarantor institution" with the exchange agent; and
- the exchange agent receives all physically tendered existing debentures, in proper form for transfer, or a book-entry confirmation of transfer of the existing debentures into the exchange agent's account at DTC, as the case may be, a properly completed and duly executed Letter of Transmittal, with any required signature guarantees, or an "agent's message" that forms a part of the book-entry confirmation, and all other required documents, in each case, within three NYSE trading days after the date of execution of the Notice of Guaranteed Delivery.

### WITHDRAWAL OF TENDERS

You can withdraw previously tendered existing debentures at any time until the exchange offer has expired. In addition, if we have not agreed to accept your existing debentures for exchange by December 11, 2003, you can

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

withdraw them at any time after that date until we do accept your existing debentures for exchange.

For a withdrawal to be effective, a written notice of withdrawal must be received by the exchange agent during the permitted periods. Any notice of withdrawal must specify the name of the person who tendered the existing debentures to be withdrawn, identify the existing debentures to be withdrawn, including the principal amount of the existing debentures, and, where existing debentures have been transmitted, specify the name in which the existing debentures are registered, if different from that of the withdrawing holder. If existing debentures have been delivered or otherwise identified to the exchange agent, then, prior to the release of the existing debentures, the withdrawing holder must also submit the serial numbers of the particular existing debentures to be withdrawn and a signed notice of withdrawal, with signatures guaranteed by an "eligible guarantor institution" unless the holder is an "eligible guarantor institution." If existing debentures have been tendered using the procedure for book-entry transfer described above, any notice of withdrawal must specify the name and number of the account at DTC to be credited with the withdrawn existing debentures and otherwise comply with the procedures of the book-entry transfer facility. All questions as to the validity, form and eligibility, including time of receipt, of these notices will be determined by us. Our determination on these matters will be final and binding.

Any existing debentures properly withdrawn will be deemed not to have been validly tendered for exchange for purposes of the exchange offer. Any existing debentures which have been tendered for exchange but which are not exchanged for any reason will be returned to the registered holder without cost to that holder promptly after withdrawal, non-acceptance of tender or termination of the exchange

22

offer. In the case of existing debentures tendered by book-entry transfer into the exchange agent's account at DTC by using the book-entry transfer procedures described above, any withdrawn or unaccepted existing debentures will be credited to the tendering holder's account at DTC. Properly withdrawn existing debentures may be retendered at any time on or prior to the expiration date of the exchange offer by following one of the procedures described above in the section entitled "Procedures for Tendering existing debentures."

### EXCHANGE AGENT

We have appointed LaSalle Bank, National Association as the exchange agent for the exchange offer. We will pay the exchange agent customary fees for its services and reimburse the exchange agent for its reasonable out-of-pocket expenses incurred in connection with the provision of these services. We will also pay the exchange agent compensation for services as trustee under the new debenture indenture and certain of its expenses related thereto.

### EXPENSES

The maximum amount of consideration required by us to consummate the exchange offer and to pay related expenses is approximately \$380,000. We will use available cash to pay expenses related to the exchange offer.

### RECOMMENDATION

We are not making any recommendation regarding whether you should tender your existing debentures in the exchange offer and, accordingly, you must



## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

make your own determination as to whether to tender your existing debentures for exchange and accept the new debentures we propose to issue to you.

### USE OF SECURITIES ACQUIRED

We will not receive any cash proceeds from the exchange offer. All existing debentures that are properly tendered and not withdrawn in the exchange offer and accepted by us will be retired and cancelled.

### SOLICITATION

The solicitation is being made by us. We have engaged D.F. King & Co., Inc. as the information agent for the exchange offer to assist us in distributing this Offering Memorandum and the other exchange offer materials to the holders of the existing debentures. We will pay the information agent customary fees for its services and reimburse the exchange agent for its reasonable out-of-pocket expenses incurred in connection with the provision of these services. We will not make any payment to brokers, dealers or others soliciting acceptances of the exchange offer. We will, however, reimburse reasonable expenses incurred by brokers and dealers in forwarding this Offering Memorandum and the other exchange offer materials to the holders of the existing debentures. Solicitations by us may be made by telephone, facsimile or in person by our officers and regular employees.

### TRANSFER TAXES

You will not be obligated to pay any transfer taxes in connection with the tender of existing debentures in the exchange offer unless you instruct us to register your new debentures in the name of, or request that existing debentures not tendered or not accepted in the exchange offer be returned to, a

23

person other than the registered tendering holder. In those cases, you will be responsible for the payment of any applicable transfer tax.

### REQUESTS FOR ASSISTANCE AND ADDITIONAL INFORMATION

All completed Letters of Transmittal and "agent's messages" should be directed to the exchange agent, at the address set forth on the front and back cover pages of this Offering Memorandum. All questions regarding the procedures for tendering in the exchange offer and requests for assistance in tendering your existing debentures should also be directed to the exchange agent, at the telephone number or address set forth on the front and back cover pages of this Offering Memorandum.

Delivery of a Letter of Transmittal or an "agent's message" other than as described in this section of the Offering Memorandum is not valid delivery of the Letter of Transmittal or "agent's message."

Requests for additional copies of this Offering Memorandum, the enclosed Letter of Transmittal, the enclosed form of Notice of Guaranteed Delivery, or our Annual Report on Form 10-K for the fiscal year ended September 30, 2002 or Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2003, may be directed to the exchange agent, at one of the telephone numbers or the address set forth on the back cover page of this Offering Memorandum.

MATERIAL UNITED STATES FEDERAL INCOME TAX  
CONSIDERATIONS OF THE EXCHANGE OFFER

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

The following discussion summarizes the material U.S. federal income tax consequences to U.S. holders of the existing debentures, of the Exchange Offer and of the acquisition, ownership conversion and disposition of the new debentures. A U.S. holder is:

- an individual citizen or resident of the United States;
- a corporation created or organized in or under the laws of the United States or any political subdivision thereof;
- an estate the income of which is includible in gross income for U.S. federal income taxation regardless of its source;
- a trust if a court in the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have the authority to control all substantial decisions of the trust; and
- any other person treated as a resident of the United States for federal income tax purposes.

This discussion does not purport to describe all of the tax considerations that may be relevant to a holder of existing debentures or new debentures. The following summary deals only with existing debentures that are, and new debentures that will be, held as capital assets by U.S. holders and does not deal with persons that are subject to special tax rules, such as:

- dealers or traders in securities or currencies;
- financial institutions or other U.S. holders that treat income in respect of the existing debentures or new debentures as financial services income;

24

- insurance companies;
- tax-exempt entities;
- persons holding existing debentures or new debentures as part of a straddle, conversion transaction or other arrangement involving more than one position; or
- persons whose "functional currency" is not the U.S. dollar.

The discussion below is based upon the provisions of the U.S. Internal Revenue Code of 1986, as amended, and regulations, rulings and judicial decisions thereunder as of the date of this Offering. Any of these authorities may be repealed, revoked, or modified, possibly with retroactive effect, so as to result in U.S. federal income tax consequences different from those described below. YOU ARE ADVISED TO CONSULT YOUR OWN TAX ADVISOR AS TO THE U.S. FEDERAL, STATE, LOCAL AND OTHER TAX CONSEQUENCES OF THE EXCHANGE OFFER AND OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF THE NEW DEBENTURES.

### TAX TREATMENT OF THE EXCHANGE OFFER

#### NON-RECOGNITION OF GAIN OR LOSS

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

The exchange by an exchanging U.S. holder of the existing debentures for the new debentures will be treated as a non-taxable exchange to the U.S. holder.

### INTEREST PAYMENTS

An exchanging U.S. holder must recognize taxable ordinary income with respect to any accrued interest on the existing debentures when we pay such interest with the first payment of interest on the new debentures after the exchange, unless the holder has already included such interest in income under the accrual method of accounting.

### TAX BASIS AND HOLDING PERIOD

The tax basis of the new debentures received in the hands of the U.S. holder will be equal to the basis of the U.S. holder in the existing debentures. The holding period of the new debentures include the holding period of the existing debentures.

### TAX TREATMENT OF THE NEW DEBENTURES

#### INTEREST PAYMENTS

Interest on a new debenture will be taxable to a U.S. holder as ordinary interest income at the time that the interest is received or is accrued, in accordance with the U.S. holder's method of accounting for federal income tax purposes.

#### ORIGINAL ISSUE DISCOUNT

An exchanging U.S. holder will have original issue discount ("OID") on a new debenture to the extent that the stated redemption price at maturity of the new debenture exceeds the issue price of the new debenture by more than a de minimis amount (i.e., 1/4 of 1 percent of the principal amount multiplied by the number of complete years to maturity of the new debentures on the date of exchange). The stated redemption price at maturity of a new debenture is the sum of all payments to be received on the new

25

debenture (other than payments of "qualified stated interest," which is stated interest that is unconditionally payable at least annually at a single fixed rate during the entire term of a debt obligation) and is generally equal to its principal amount. If the issue price of the new debentures is equal to or greater than their principal amount, then the new debentures will not be treated as issued with OID.

If, on the other hand, the issue price of the new debentures is less than their principal amount, then the new debentures will be treated as issued with OID.

Subject to the discussion of amortizable bond premium below, a U.S. holder of a new debenture issued with OID must include OID in income, as ordinary interest income, on a constant-yield-to-maturity basis whether or not cash attributable to such income is actually received. The amount of OID includable in income or "accrued" by a U.S. holder is the sum of the daily portions of OID with respect to the new debenture for each day during the taxable year or portion of the taxable year on which the U.S. holder holds the

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

new debenture. In general, the effect of OID is that U.S. holders will realize additional interest income on the new debentures over the term of the new debentures. A U.S. holder will increase its tax basis in the new debentures by the amount of any OID included in income.

### AMORTIZABLE BOND PREMIUM

If a U.S. holder receives a new debenture in the exchange and has a tax basis in the new debenture (determined as described above under "Tax Treatment of the Exchange Offer -- Tax Basis and Holding Period") in excess of the stated principal amount of the new debenture, the U.S. holder will be considered to have received the new debenture with amortizable bond premium equal to such excess (reduced by any value attributable to the conversion feature of the existing debenture). A U.S. holder generally may elect to amortize bond premium over the remaining term of the new debenture on a constant-yield-to-maturity basis. The amount amortized in any taxable year will be treated as a reduction of the U.S. holder's interest income from the new debenture. A U.S. holder that elects to amortize bond premium must reduce its tax basis in a new debenture by the amount of the premium amortized in any year. An election to amortize bond premium for a specific taxable year will apply to all the U.S. holder's debt instruments held on or after the first day of that taxable year.

If a U.S. holder does not make this election, the amount of the premium will decrease the gain or increase the loss otherwise recognized on a taxable disposition of the new debenture. U.S. holders should consult their own tax advisors with respect to making an election to amortize bond premium.

### ELECTION TO TREAT ALL INTEREST AS OID

A U.S. holder may elect to include in gross income all interest that accrues on a new debenture on a constant-yield-to-maturity basis with the modifications described below. For purposes of this election, interest includes stated interest and OID, as adjusted by any acquisition premium or amortizable bond premium. If a U.S. holder makes this election for a new debenture with amortizable bond premium, the election is treated as an election under the amortizable bond premium provisions described above, and the electing U.S. holder will be required to amortize bond premium in income currently for all of the U.S. holder's other debt instruments with amortizable bond premium. The election is made for the taxable year in which the U.S. holder acquired the new debenture, and may not be revoked without the consent of the Internal Revenue Service. U.S. holders should consult their own tax advisors with respect to making this election.

### SALE, EXCHANGE, REDEMPTION AND RETIREMENT OF NEW DEBENTURES

As discussed above, a U.S. holder's initial tax basis in a new debenture will be increased by the amount of any OID or market discount included in the U.S. holder's income with respect to the new

debenture and reduced by the amount of any amortized bond premium and any payments on the new debenture (other than payments of qualified stated interest). A U.S. holder generally will recognize gain or loss on the sale, exchange, redemption or retirement of a new debenture, in an amount equal to the difference between the amount realized in the transaction (other than amounts attributable to accrued but unpaid interest, which will be taxable as ordinary income) and the adjusted tax basis of the new debenture. Gain or loss recognized on the sale or retirement of a new debenture by a U.S. holder that held the new

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

debenture as a capital asset will be treated as capital gain or loss. If the new debentures have been held for more than one year, the capital gain or loss will be long-term capital gain or loss.

### CONVERSION OF THE NEW DEBENTURES

U.S. holders generally will not recognize any gain or loss on the conversion of a new debenture into common stock. If a U.S. holder receives cash in lieu of fractional shares of common stock, however, such holder will be treated as if it received the fractional shares of common stock and then had them redeemed for cash. Accordingly, such holder would recognize gain or loss equal to the difference between the cash received and that portion of its basis in the common stock that is attributable to the fractional shares of common stock. A U.S. holder's aggregate basis in the common stock will equal the U.S. holder's adjusted basis in the new debenture immediately prior to conversion. The holding period for the common stock will include the holding period for the new debentures.

### DIVIDENDS

If, after a U.S. holder converts a new debenture into common stock, we make a distribution in respect of the common stock, the distribution will be treated as a dividend that will be taxable to the U.S. holder as ordinary income, to the extent it is paid from our current or accumulated earnings and profits. If the distribution exceeds our current and accumulated earnings and profits, the excess will be treated first as a tax-free return of investment up to the basis in the common stock. Any excess will be treated as capital gain. If a U.S. holder is a U.S. corporation, the U.S. holder generally will be able to claim a deduction equal to a portion of any dividends received.

If the new debentures allow for adjustment of the conversion price which allow a U.S. holder to receive more common stock, the right to receive more common stock on conversion may increase the U.S. holder's proportionate interest in our earnings and profits or assets. In that case, the U.S. holder would be treated as having received a dividend in the form of common stock. Such a constructive stock dividend could be taxable to the U.S. holder, whether or not cash or other property is actually received. A taxable constructive stock dividend would result, for example, if the conversion price were adjusted to compensate a U.S. holder for distributions of cash or property to our shareholders.

Not all changes in conversion price that allow U.S. holders to receive more common stock on conversion, however, will increase a U.S. holder's proportionate interest in the company. For instance, a change in conversion price could simply prevent the dilution of a U.S. holder's interest upon a stock split or other change in capital structure. Changes of this type, if made by a bona fide, reasonable adjustment formula, are not treated as constructive stock dividends. Conversely, if an event occurs that dilutes a U.S. holder's interests and the conversion price is not adjusted, the resulting increase in the proportionate interests of our shareholders could be treated as a taxable stock dividend to them. Any taxable constructive stock dividends resulting from a change to, or failure to change, the conversion price would be treated in the same manner as dividends paid in cash or other property. They would result in ordinary income to the U.S. holder, to the extent of our current or accumulated earnings and profits.

### SALE OR EXCHANGE OF COMMON STOCK

U.S. holders generally will recognize capital gain or loss on a sale or

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

exchange of common stock. The gain or loss will equal the difference between the amount realized on the sale and the adjusted tax basis in the common stock. If the common stock have been held for more than one year, the gain or loss recognized by a U.S. holder on a sale or exchange of common stock will be long-term capital gain or loss.

### INFORMATION REPORTING AND BACKUP WITHHOLDING

For each calendar year in which the new debentures are outstanding, we are required to provide the Internal Revenue Service with certain information, including a U.S. holder's name, address and taxpayer identification number (either the U.S. holder's Social Security number or its employer identification number, as the case may be), the aggregate amount of principal and interest paid to that holder during the calendar year and the amount of tax withheld, if any. This obligation, however, does not apply with respect to certain U.S. holders, including corporations, tax-exempt organizations, qualified pension and profit-sharing trusts and individual retirement accounts.

If a U.S. holder subject to the reporting requirements described above fails to supply its correct taxpayer identification number in the manner required by applicable law or under-reports its tax liability, we, our agents or paying agents or a broker may be required to make "backup" withholding of tax on payments of:

- principal and interest made on a new debenture;
- the proceeds of a sale or exchange of a new debenture before maturity;
- dividends on common stock; and
- the proceeds of a sale or exchange of common stock.

As of December 1, 2002, the backup-withholding rate for applicable payments made through December 31, 2003 was 30%. The backup withholding rate is 29% for 2004 and 2005, and 28% for 2006 and thereafter (subject to possible increase after 2010). This backup withholding is not an additional tax and may be credited against the U.S. holder's federal income tax liability, provided that the U.S. holder furnishes the required information to the Internal Revenue Service.

### TAX CONSEQUENCES TO NON-PARTICIPANTS

A U.S. holder that does not participate in the exchange offer and instead retains its existing debentures will not recognize any gain or loss as a result of the consummation of the exchange offer.

### DESCRIPTION OF NEW DEBENTURES

We will issue the new debentures under an indenture dated as of October 1, 2003, between LaSalle Bank, National Association, as trustee, and us. The following summarizes the material provisions of the indenture and the new debentures and does not purport to be complete and is subject to, and qualified by reference to, all of the provisions of the indenture and the new debentures which define your rights as a holder of new debentures.

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

### GENERAL

The new debentures represent our unsecured general obligations, subordinate in right of payment to certain other obligations as described below under "Subordination of New Debentures" and convertible into our common stock as described under "Conversion of New Debentures." The new debentures will be issued in fully registered form only in denominations of \$1,000 or any integral multiple thereof and will mature on September 1, 2013.

The new debentures bear interest at 5% payable semi-annually on March 1 and September 1, to holders of record at the close of business on the preceding February 15 and August 15, respectively.

Principal and premium, if any, will be paid and the new debentures may be presented for conversion, registration of transfer, and exchange, without service charge, at the corporate trust office of the trustee in Chicago, Illinois. Interest will be paid by checks mailed to holders of record unless other arrangements are made.

### CONVERSION OF NEW DEBENTURES

The holders of new debentures are entitled at any time before the close of business on September 1, 2013, subject to prior redemption, to convert their all or a portion of their debentures into shares of our common stock, at the conversion price. The conversion price is currently \$14.50 and is subject to adjustment as described below. Except as described below, no adjustment will be made on conversion of any new debenture for interest accrued thereon or for dividends on any shares of common stock issued.

If any new debenture not called for redemption is converted between a record date for the payment of interest and the related interest payment date, the new debenture must be accompanied by funds equal to the interest payable on such interest payment date on the principal amount so converted. We are not permitted to issue fractional shares of common stock upon conversion of new debentures. In lieu thereof, will pay a cash adjustment based upon the market price of the common stock on the last trading day prior to the date of conversion. In the case of new debentures called for redemption, conversion rights will expire at the close of business on the redemption date.

The conversion price is subject to adjustment as provided in the indenture upon certain events including:

- o the issuance of shares of our common stock as a dividend or distribution on the common stock;
- o subdivisions, combinations, and reclassifications of our common stock;

29

- o the issuance to all holders of common stock of certain rights or warrants entitling them for a period not exceeding 45 days to subscribe for common stock at less than the then-current market price; and
- o the distribution to all holders of common stock of any of our securities (other than common stock) or evidences of indebtedness

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

or of assets (excluding cash dividends or distributions from retained earnings) or rights or warrants to subscribe for or purchase any of our securities (excluding those referred to above).

No adjustment in the conversion price will be required unless such adjustment would require a change of at least 1% in the conversion price then in effect. However, any adjustment that would otherwise be required to be made shall be carried forward and taken into account in any subsequent adjustment.

We have the right to make reductions in the conversion price, in addition to those required by the foregoing provisions, as we in our discretion determine to be advisable in order that certain share-related distributions made by us to our shareholders will not be taxable. Except as stated above, the conversion price will not be adjusted for the issuance of shares of common stock or any securities convertible into or exchangeable for common stock, or carrying the right to purchase any of the foregoing, in exchange for cash, property, or services.

In the case of a consolidation, merger or statutory share exchange involving us as a result of which holders of common stock will be entitled to receive stock, securities or other property or assets (including cash) with respect to or in exchange for shares of common stock or in the case of a sale or conveyance to another corporation of all or substantially all of our property and assets, the holders of the new debentures then outstanding will be entitled thereafter to convert their new debentures into the kind and amount of shares of stock, other securities or other property or assets which they would have owned or been entitled to receive upon such consolidation, merger, statutory share exchange, sale or conveyance had such new debentures been converted to shares of common stock immediately prior to such consolidation, merger, statutory share exchange, sale or conveyance.

In the event of a taxable distribution to holders of common stock which results in an adjustment of the conversion price, the holders of new debentures may, in certain circumstances, be deemed to have received a distribution subject to United States income tax as a dividend. The absence of such an adjustment in certain other circumstances may also result in a taxable dividend to the holders of common stock.

### OPTIONAL REDEMPTION

The new debentures will be redeemable on at least 15 and not more than 60 days' notice, at our option, as a whole or in part, at any time after September 1, 2004, at the following prices (expressed as percentages of the principal amount), together with accrued interest to the date fixed for redemption:

- o If redeemed during the 12-month period beginning September 1, 2004 - 103%
- o If redeemed during the 12-month period beginning September 1, 2005 - 102%
- o If redeemed during the 12-month period beginning September 1, 2006 - 101%
- o If redeemed on or after September 1, 2007 - 100%



## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

### SUBORDINATION OF NEW DEBENTURES

The indebtedness evidenced by the new debentures is subordinate to the prior payment in full of all present and future senior indebtedness as provided in the indenture. If an event of default in the payment of principal, interest or rental on any senior indebtedness continues beyond any applicable grace period, we may not make any payment of principal of, premium, if any, or interest on the new debentures. In addition, upon any distribution of our assets or upon our dissolution, winding up, liquidation or reorganization, the payment of the principal of, premium, if any, and interest on the new debentures is subordinated to the extent provided in the indenture in right of payment to the prior payment in full of all senior indebtedness. As a result of this subordination, in the event of our dissolution, holders of senior indebtedness may receive more, ratably, and holders of the new debentures may receive less, ratably, than our other creditors or may receive no consideration at all. Such subordination will not prevent the occurrence of any event of default under the Indenture.

The term senior indebtedness includes the following:

- o Principal of and premium, if any, and interest on our indebtedness for money borrowed (including any indebtedness secured by a mortgage or other lien which is given to secure all or part of the purchase price of property subject thereof, whether given to the vendor of such property or to another, or existing on property at the time of acquisition thereof) evidenced by notes or other written obligations;
- o Principal of and premium, if any, and interest on our indebtedness evidenced by our notes, debentures, bonds or other securities;
- o The amount of our liability determined under generally accepted accounting principles under any lease required to be classified as a liability on our balance sheet;
- o Principal of and premium, if any, and interest on indebtedness of others of the kinds described in either of the first two bullet points above or, to the extent set forth in the third bullet point above, leases of others of the kind described in such bullet point assumed by or guaranteed in any manner by us or in effect guaranteed by the us through an agreement to purchase, contingent or otherwise; and
- o Principal of and premium, if any, and interest on renewals, extensions, or refundings of indebtedness of the kinds described in first, second or fourth bullet point above or, to the extent set forth in the third bullet point above, renewals or extensions of leases of the kinds described in either of the third or fourth bullet point above.

unless, in the case of any particular indebtedness, lease, renewal, extension, or refunding, the instrument or lease creating or evidencing the same or the assumption or guarantee of the same expressly provides that such indebtedness, lease, renewal, extension, or refunding is subordinate to any other indebtedness of ours or that such indebtedness, lease, renewal, extension, or refunding is not superior in right of payment to the new debentures.

The indenture permits the trustee to become our creditor and does not preclude the trustee from enforcing its rights as a creditor, including rights as a holder of senior indebtedness. The indenture does not limit the amount of senior indebtedness we may incur.

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

### REDEMPTION OF NEW DEBENTURES AT THE OPTION OF THE HOLDER

Upon the occurrence of specified events, which we call repurchase events, each holder of new debentures shall have the right to require us to repurchase all or any part (equal to \$1,000 or an integral multiple thereof) of such holder's new debentures pursuant to the repurchase offer described below at a

31

purchase price equal to 100% of the aggregate principal amount of the new debentures plus accrued and unpaid interest, if any, to the date of purchase. We refer to the price to be paid to repurchase the new debentures as the repurchase price.

Within 30 days after the occurrence of a repurchase event, we must mail a notice to each holder stating, among other things:

- o the repurchase payment and the repurchase date, which shall not be earlier than 45 days nor later than 60 days from the date such notice is mailed or such later date as may be necessary for us to comply with the requirements of the Securities Exchange Act of 1934;
- o that any new debenture not tendered will continue to accrue interest;
- o that, unless we default in the payment of the repurchase payment, all new debentures accepted for payment pursuant to the repurchase offer shall cease to accrue interest after the repurchase date; and
- o certain other procedures that a holder must follow to accept a repurchase offer or to withdraw such acceptance.

We will comply with any applicable requirements of the Securities Exchange Act of 1934 and other securities laws and regulations governing the repurchase of the new debentures in connection with a repurchase event and may modify a repurchase offer to effect such compliance.

A repurchase event is generally defined to include:

- o the acquisition of 50% or more of our voting stock by a person or group, other than any current holder of 5% or more of our common stock (or a group including such a holder);
- o a change, over a two-year period, in the composition of our board of directors such that, with limited exceptions, the board members at the beginning of the period no longer constitute a majority of the board;
- o certain consolidations and mergers involving us or sales of our assets, if the primary effect is that, after the transaction, a person or group, other than a current holder of 5% or more of our common stock (or group including such a holder), has more than 50% of the ordinary voting power of the surviving corporation;
- o our acquisition of over 30% of the outstanding shares of our

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

capital stock during any 12-month period; and

- o certain distributions in respect of our capital stock or acquisitions by us of our capital stock, if, in either case, the sum of the ratio of the fair market value of the price paid in the current distribution or acquisition to the then-fair market value of our outstanding capital stock plus the similar ratios for all other distributions or acquisitions, respectively, during the prior 12-month period, exceeds 30%.

For purposes of the repurchase event tests, our voting stock includes our common stock plus any other class or classes of stock which may be issued and have general voting power in the election of our board of directors and our capital stock means any stock which does not have dividend or liquidation priority over other stock of ours, regardless of relative voting powers. Currently, our only voting stock and capital stock is our common stock.

32

On the repurchase date, we will deposit with the trustee an amount equal to the repurchase payment in respect of all new debentures or portions thereof that have been tendered. The trustee shall promptly mail to each holder of new debentures accepted for payment an amount equal to the repurchase price for such new debentures, and the trustee shall promptly authenticate and mail to each holder a new debenture equal in principal amount to any unpurchased portion of the new debentures surrendered.

Except as described above with respect to a repurchase event, the indenture does not contain any other provisions that permit the holders of the new debentures to require that we repurchase or redeem the new debentures in the event of a takeover or similar transaction. The provisions of the indenture relating to the purchase of new debentures upon a repurchase event may impede the completion of a merger, tender offer or other takeover attempt.

Any future credit agreements or other agreements relating to senior indebtedness to which we become a party may prohibit us from purchasing any new debentures or may provide that certain change in control events with respect to us would constitute a default under such agreements. If a repurchase event occurs at a time when we are prohibited from purchasing new debentures, we could seek the consent of its lenders for the purchase of new debentures or could attempt to refinance the borrowings that contain such prohibition. If we do not obtain such a consent or repay such borrowings, we will remain prohibited from purchasing new debentures. In such case, our failure to purchase tendered new debentures would constitute an event of default under the indenture. In such circumstances, the subordination provisions in the indenture would restrict payments to the holders of new debentures.

### EVENTS OF DEFAULT

An event of default as provided in the indenture includes:

- o default in the payment of any installment of interest upon any of the new debentures as and when the same shall become due and payable, and continuance of such default for a period of 15 days;
- o default in payment of principal or premium, if any, on the new debentures when the same becomes due and payable at maturity, upon redemption or otherwise, whether or not prohibited by the subordination provisions of the indenture;

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

- o default for 30 days after notice in the observance or performance of any other covenant in the indenture;
- o default under any obligations for money borrowed of \$1,000,000 or more; or
- o certain events involving our bankruptcy, insolvency, or reorganization.

The indenture provides that the trustee is required, within 90 days after the occurrence of a default which is known to the trustee and is continuing, to give to the holders of the new debentures notice of such default. The trustee is, however, except in the case of default in the payment of principal or premium, if any, or interest on any of the new debentures, in withholding such notice if it in good faith determines that the withholding of such notice is in the interest of the holders of the new debentures.

The indenture provides that if any event of default has occurred and is continuing, the trustee or the holders of not less than 25% in principal amount of the new debentures then outstanding may declare the principal of all the new debentures to be due and payable, but if we cure all defaults (other than the nonpayment of interest and premium, if any, on and principal of any new debentures which shall have become due solely by reason of acceleration) and certain other conditions are met, such

33

declaration may be annulled and past defaults may be waived by the holders of a majority in principal amount of the new debentures then outstanding.

The holders of a majority in principal amount of the new debentures then outstanding will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee subject to certain limitations specified in the indenture.

In certain cases, the holders of a majority in principal amount of the outstanding new debentures may on behalf of the holders of all new debentures waive any past default or event of default except, unless cured, a default in the payment of the principal of, premium, if any, or interest on any of the new debentures (other than the nonpayment interest and premium, if any, on and principal of any new debentures which shall become due by acceleration) or a default relating to an obligation of ours which cannot be modified without the consent of the holder of each new debenture affected.

### MERGERS AND SALES OF ASSETS

Subject to the provisions described above under "Redemption of New debentures at the Option of the Holder," we may consolidate with or merge into any other corporation, or sell or transfer all or substantially all of its assets to any corporation, provided that the successor corporation shall be a corporation organized and existing under the laws of the United States or any State thereof and shall assume all of our obligations under the indenture.

### MODIFICATION OF THE INDENTURE

The indenture permits us and the trustee, with the consent of the holders of not less than a majority in principal amount of the new debentures at

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

the time outstanding, to modify the indenture or any supplemental indenture or the rights of the holders of the new debentures except that no such modification shall, without the consent of the holder of each new debenture affected:

- o extend the fixed maturity of any new debenture, reduce the rate or extend the time of payment of interest thereon, reduce the principal amount thereof or redemption premium thereon, impair or affect the right of a holder to institute suit for the payment thereof, change the currency in which the new debentures are payable or impair the right to convert the new debentures into shares of common stock subject to the terms set forth in the indenture, or
- o reduce the aforesaid percentage of new debentures, the consent of the holders of which is required for any such modification.

### MISCELLANEOUS

No holder of a new debenture may institute any action against us under the indenture (except actions for payment of overdue principal, premium, if any, or interest or the conversion of the new debentures) unless the holders of at least 25% of the principal amount of new debentures then outstanding shall have requested the trustee to institute such action, and the trustee shall not have instituted such action within 60 days of such request.

Our directors, officers, employees and shareholders do not have any liability for any of our obligations under the new debentures or the indenture, or for any claim based on, in respect of or by reason of, such obligations or their creation. Each holder of new debentures by accepting a new debenture waives and releases all such liability. The waiver and release are part of the consideration for the issuance of the new debentures.

34

Whether or not required by the rules and regulations of the SEC, so long as any new debentures are outstanding, we furnish holders of new debentures all quarterly and annual information that would be required to be contained in a filing with the SEC on Forms 10-Q and 10-K as if we were required to file such forms.

### CONCERNING THE TRUSTEE

LaSalle Bank, National Association, the trustee, may at times be a depository for funds of, make loans to or perform services for us and our subsidiaries in the normal course of business. The indenture does not preclude the trustee from enforcing its rights as a creditor, including rights as a holder of senior indebtedness.

### COMPARISON OF TERMS OF EXISTING DEBENTURES AND NEW DEBENTURES

Set forth below is a comparison of the terms of the new debentures and the new debentures. The terms of the new debentures are substantially identical to the terms of the new debentures except for the material differences which are summarized below.

EXISTING DEBENTURES

NEW DEBENTURES

Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

ISSUE	7% Convertible Subordinated Debentures due 2006	5% Convertible Subord Debentures due 2013
ISSUER	Meridian Bioscience, Inc.	Meridian Bioscience,
SECURITY	Unsecured	Unsecured
ISSUE DATE	September 27, 1996	Upon the closing of t offer and the exchang debentures for existi expected to occur on 2003, if all of the c exchange offer are sa
INTEREST RATE	7%	5%
PRINCIPAL AMOUNT OUTSTANDING	\$20,000,000	Up to \$16,000,000
MATURITY DATE	September 1, 2006	September 1, 2013
INTEREST PAYMENT DATES	March 1 and September 1	March 1 and September March 1, 2004
CONVERSION	Convertible into shares of our common stock at any time prior to maturity, unless previously redeemed or repurchased, at a conversion price of \$16.09 per share, subject to adjustment in certain events.	Convertible into shar stock at any time pri unless previously red repurchased, at a con \$14.50 per share, sub adjustment in certain
OPTIONAL REDEMPTION	Beginning September 1, 2003, the existing debentures became redeemable at our option at 100% of principal amount, plus accrued interest.	Not redeemable before Redeemable, in whole 102% and 101% of prin accrued interest, dur periods beginning on 2005 and 2006, respec redeemable, in whole principal amount plus
SUBORDINATION	The existing debentures are subordinated to all of our existing and future senior indebtedness (as defined)	The new debentures an to all of our existin senior indebtedness (
TRUSTEE	U. S. Bank, N.A.	LaSalle Bank, Nationa

35

DESCRIPTION OF COMMON STOCK

The following summary of some provisions of our common stock is not complete. You should refer to our articles of incorporation and regulations,

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

which are incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and applicable law for more information.

### GENERAL

Our articles of incorporation provide that we can issue up to 50,000,000 shares of common stock. As of September 30, 2003, we had 14,728,590 shares of common stock outstanding. Holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of shareholders. Shareholders do not have the right to cumulate their votes in the election of directors.

Holders of our common stock are entitled to share in dividends as declared by our board of directors in its discretion. In the event of our liquidation, each outstanding share of common stock entitles its holder to participate ratably in the assets remaining after payment of liabilities. Shareholders have no preemptive or other rights to subscribe for or purchase additional shares of any class of our stock or any other securities of ours. We do not have any redemption or sinking fund provisions with regard to our common stock. All outstanding shares of common stock are fully paid, valid issued and non-assessable.

The vote of holders of 66-2/3% of all outstanding shares of common stock is required to amend our articles of incorporation and to approve mergers, reorganizations, and similar transactions.

### PROVISIONS AFFECTING BUSINESS COMBINATIONS

Our articles of incorporation require approval by 66-2/3% of the voting power of disinterested shareholders for any business combination between an interested shareholder and us for five years after such party became an interested shareholder. An interested shareholder is one beneficially owning 15%

36

or more of the voting power. Business combinations include mergers, sales of assets and similar transactions. Our articles of incorporation also require any person who becomes an interested shareholder to offer to purchase all of our voting securities and securities convertible into or constituting warrants or options to purchase our voting securities within 25 days after achieving 15% ownership. The price to be paid would be the higher of the highest price paid by the interested shareholder in acquiring such beneficial ownership or the highest trading price during the 45 day period commencing 70 days prior to the date that such person became an interested shareholder. These provisions are not applicable if the proposed business combination is approved prior to its consummation by a majority of disinterested directors or if the transaction by which a person becomes an interested shareholder is approved at any time prior to that time by a majority of disinterested directors.

We are also subject to Chapter 1704 of the Ohio Revised Code which prohibits us from entering into transactions with persons owning 10% or more of our outstanding voting power for at least three years after attaining 10% ownership unless the Board of Directors has approved the acquisitions of shares resulting in such ownership. We are also subject to Section 1701.831 of the Ohio General Corporation Law requiring shareholder approval of acquisitions by persons beyond 20%, 33-1/3% and 50% of our voting power. Ohio Revised Code Section 1707.043 requires a person or entity making a proposal to acquire control of us to repay us any profits made from trade in our stock within 18 months after making the control proposal.

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

These provisions of our articles of incorporation and Ohio law would be important in any attempted takeover of us and could operate, depending on how utilized by the Board of Directors, either to discourage a hostile takeover or to enable the Board to negotiate a higher price than may be initially proposed in any such situation.

### DESCRIPTION OF OTHER INDEBTEDNESS

We have a \$25,000,000 credit facility with a commercial bank. This facility includes \$5,000,000 of term debt and capital lease capacity and a \$20,000,000 revolving line of credit which bears interest at a LIBOR based rate, and expires in September 2004. This line of credit is secured by our business assets except for those of specified subsidiaries. Borrowings of \$463,000 were outstanding on this line of credit at September 30, 2003 at a weighted average interest rate of 1.87%. Available borrowings under this line of credit were \$19,537,000 at September 30, 2003. In connection with this bank credit arrangement, we are required to comply with financial covenants that limit the amount of debt obligations, require a minimum amount of tangible net worth, and require a minimum amount of fixed charge coverage. We are in compliance with all covenants. We are also required to maintain a cash compensating balance with the bank in the amount \$600,000 pursuant to this bank credit arrangement.

### LEGAL MATTERS

The validity of the debentures offered hereby will be passed upon for us by Keating, Muething & Klekamp, P.L.L., Cincinnati, Ohio.

### INDEPENDENT AUDITORS

The financial statements incorporated in this Offering Memorandum by reference to the Annual Report on Form 10-K for Meridian Bioscience, Inc. for the year ended September 30, 2002 have been audited by PricewaterhouseCoopers LLP, independent accountants, as stated in their report thereto.

Our consolidated financial statements as of September 30, 2001 and for the two years then ended, which are incorporated by reference in this Offering Memorandum, have been audited by

37

Arthur Andersen LLP, independent public accountants, as indicated in their report with respect thereto. Arthur Andersen LLP has not consented to the inclusion of their report in the Offering Memorandum. Because Arthur Andersen LLP has not consented to the inclusion of their report in the Offering Memorandum, it may become more difficult for you to seek remedies against Arthur Andersen LLP in connection with any material misstatement or omission that may be contained in our consolidated financial statements and schedules for such periods. In particular, and without limitation, relief that may be available to investors under the federal securities laws against accounting firms may not be available against Arthur Andersen LLP.

### WHERE YOU CAN FIND MORE INFORMATION

We are subject to the information and reporting requirements of the Securities Exchange Act of 1934, under which we file annual, quarterly and special reports, proxy statements and other information with the Securities and Exchange Commission. You may read and copy this information at the following location of the Securities and Exchange Commission:



Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

Public Reference Room  
450 Fifth Street, N.W.  
Room 1024  
Washington, D.C. 20549

You may also obtain copies of this information by mail from the Public Reference Section of the Securities and Exchange Commission, 450 Fifth Street, N.W., Room 1024, Washington, DC 20549, at prescribed rates. Please call the Securities and Exchange Commission at (800) 732-0330 for further information about the Public Reference Room.

The Securities and Exchange Commission also maintains an internet website that contains reports, proxy statements and other information about issuers that file electronically with the Securities and Exchange Commission. The address of that site is [www.sec.gov](http://www.sec.gov). SEC filings may also be accessed free of charge through our Internet site at [www.meridianbioscience.com](http://www.meridianbioscience.com).

38

INCORPORATION BY REFERENCE

We are "incorporating by reference" into this prospectus certain information that we file with the Securities and Exchange Commission, which means that we are disclosing important information to you by referring you to those documents. The information incorporated by reference is deemed to be part of this Offering Memorandum, except for any information superseded by information contained directly in this Offering Memorandum. This Offering Memorandum incorporates by reference the documents set forth below that we have previously filed with the Securities and Exchange Commission. These documents contain important information about us and our finances.

SEC Filings (File No. 0-14902) -----	Period -----
Annual Report on Form 10-K Quarterly Reports on Form 10-Q	Year Ended September 30, 2002 Quarters Ended December 31, 2002, March 31, 2003 and June 30, 2003
Current Report on Form 8-K Registration Statement on Form 8-A	September 25, 2003 Filed on August 15, 1986

You may request a copy of these filings, at no cost, by writing or calling us at the following address or telephone number:

Melissa A. Lueke  
Vice President, Chief Financial Officer and Secretary  
Meridian Bioscience, Inc.  
3471 River Hills Drive  
Cincinnati, Ohio 45244  
(513) 271-3700

Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this Offering Memorandum.

Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

Information contained on our website is not intended to be incorporated by reference in this Offering Memorandum and you should not consider that information a part of this Offering Memorandum.

You should rely only on the information incorporated by reference or provided in this Offering Memorandum. No one else is authorized to provide you with any other information or any different information. We are not making an offer of securities in any state where an offer is not permitted. You should not assume that the information in this Offering Memorandum is accurate as of any date other than the date on the front of this document.

39

THE EXCHANGE AGENT FOR THE EXCHANGE OFFER IS:

LaSalle Bank, National Association  
135 South LaSalle Street, Suite 1811  
Chicago, IL 60603  
Attention: Corp. Trust Operations  
Phone: (312) 904-2450  
Toll-free: (800) 246-5761

THE INFORMATION AGENT FOR THE EXCHANGE OFFER IS:

D.F. KING & CO., INC.  
48 Wall Street  
22nd Floor  
New York, NY 10005  
Banks and Brokerage Firms, Please Call: (212) 269-5550  
All Others Call Toll-free: (888) 887-1266

LETTER OF TRANSMITTAL

MERIDIAN BIOSCIENCE, INC.

OFFER TO EXCHANGE  
5% CONVERTIBLE SUBORDINATED DEBENTURES DUE 2013  
IN PRINCIPAL AMOUNT OF \$16,000,000 FOR EQUAL AMOUNT OF  
OUTSTANDING 7% CONVERTIBLE SUBORDINATED DEBENTURES DUE 2006  
PURSUANT TO THE OFFERING MEMORANDUM  
DATED NOVEMBER 12, 2003

THE EXCHANGE OFFER WILL EXPIRE AT 12:00 MIDNIGHT, EASTERN TIME,  
ON DECEMBER 11, 2003, UNLESS EXTENDED OR EARLIER TERMINATED.

THE EXCHANGE AGENT FOR THE EXCHANGE OFFER IS:

LASALLE BANK, NATIONAL ASSOCIATION

By Mail, Overnight, or  
Personal Delivery:

135 South LaSalle Street, Suite 1811  
Chicago, IL 60603  
Attn: Corp. Trust Operations

Confirm by Telephone:

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

(312) 904-2450  
Toll-Free: (800) 246-5761

DELIVERY OF THIS LETTER OF TRANSMITTAL TO AN ADDRESS OTHER THAN AS LISTED ABOVE, OR TRANSMISSION OF INSTRUCTIONS BY FACSIMILE OTHER THAN AS SET FORTH ABOVE, WILL NOT CONSTITUTE A VALID DELIVERY OF YOUR EXISTING DEBENTURES.

By signing this Letter of Transmittal, you hereby acknowledge that you have received and reviewed the Offering Memorandum, dated November 12, 2003 (the "Offering Memorandum"), of Meridian Bioscience, Inc. ("Meridian") and this Letter of Transmittal. The Offering Memorandum, together with this Letter of Transmittal, constitutes an offer to exchange (the "Exchange Offer") our 5% Convertible Subordinated Debentures due 2013 (the "New Debentures") in the principal amount of \$16,000,000 for an equal principal amount of our outstanding 7% Convertible Subordinated Debentures due 2006 (the "Existing Debentures"). This Exchange Offer is being extended to all holders of the Existing Debentures.

If you decide to tender your Existing Debentures, and we accept the Existing Debentures, this will constitute a binding agreement between you and us, subject to the terms and conditions set forth in the Offering Memorandum and this Letter of Transmittal. Unless you comply with the procedures described in the section of the Offering Memorandum entitled "The Exchange Offer -- Guaranteed Delivery Procedures," you must do one of the following on or prior to the expiration date of the Exchange Offer to participate in the Exchange Offer:

- tender your Existing Debentures by sending the certificates representing your Existing Debentures, in proper form for transfer, a properly completed and duly executed Letter of Transmittal, with any required signature guarantees, and all other documents required by this Letter of Transmittal to the Exchange Agent at the address listed above; or
- tender your Existing Debentures by using the book-entry transfer procedures described in the section of the Offering Memorandum entitled "The Exchange Offer -- Book-Entry Transfer," and transmitting this Letter of Transmittal, with any required signature guarantees, or an "agent's message" (as defined below) instead of this Letter of Transmittal to the Exchange Agent.

In order for a book-entry transfer to constitute a valid tender of your Existing Debentures in the Exchange Offer, the Exchange Agent must receive a confirmation of book-entry transfer (a "Book-Entry Confirmation") of your Existing Debentures into the Exchange Agent's account at The Depository Trust Company prior to the expiration date of the Exchange Offer. The term "agent's message" means a message, transmitted by The Depository Trust Company and received by the Exchange Agent and forming a part of the Book-Entry Confirmation, which states that The Depository Trust Company has received an express acknowledgment from you that you have received and have agreed to be bound by the terms of this Letter of Transmittal. If you use this procedure, we will be able to enforce this Letter of Transmittal against you.

The physical delivery of documents to The Depository Trust Company's book-entry transfer facility will not constitute delivery to the Exchange Agent. The procedures for book-entry transfer must be followed.

If you are a holder of Existing Debentures and wish to tender your Existing Debentures in the Exchange Offer, but the certificates for Existing Debentures are not immediately available, time will not permit your certificates for Existing Debentures or other required documents to reach the Exchange Agent before the expiration date of the Exchange Offer, or the procedure for book-entry transfer cannot be completed prior to the expiration date of the

Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

Exchange Offer, you may tender the Existing Debentures by following the procedures described in the section of the Offering Memorandum entitled "The Exchange Offer -- Guaranteed Delivery Procedures."

Only registered holders of Existing Debentures (the "Registered Holders") -- which term, for purposes of this Letter of Transmittal, includes any participant in The Depository Trust Company's system whose name appears on a security position listing as an owner of Existing Debentures -- are entitled to tender their Existing Debentures for exchange in the Exchange Offer. If you are a beneficial owner whose Existing Debentures are registered in the name of a broker, dealer, commercial bank, trust company or other nominee and you wish to tender your Existing Debentures in the Exchange Offer, you should promptly contact the person in whose name the Existing Debentures are registered and instruct that person to tender on your behalf. If you wish to tender in the Exchange Offer on your own behalf, prior to completing and executing this Letter of Transmittal and

-2-

delivering the certificates for your Existing Debentures, you must either make appropriate arrangements to register ownership of the Existing Debentures in your name or obtain a properly completed bond power from the person in whose name the Existing Debentures are registered.

You must complete this Letter of Transmittal if you are a Registered Holder of Existing Debentures -- which includes any participant in The Depository Trust Company's system whose name appears on a security position listing as an owner of Existing Debentures -- and either (1) you wish to tender the certificates representing your Existing Debentures to the Exchange Agent together with this Letter of Transmittal or (2) you wish to tender your Existing Debentures by book-entry transfer to the Exchange Agent's account at The Depository Trust Company and you elect to submit this Letter of Transmittal to the Exchange Agent instead of an "agent's message."

In order to properly complete this Letter of Transmittal, you must: (1) complete the box entitled "Description of Existing Debentures Tendered," (2) if appropriate, check and complete the boxes relating to guaranteed delivery and book-entry transfer and the box entitled "Special Payment/ Issuance Instructions" and/or "Special Delivery Instructions," (3) sign this Letter of Transmittal by completing the box entitled "Sign Here" and (4) complete the box entitled "Substitute Form W-9." By completing the box entitled "Description of Existing Debentures Tendered" and signing below, you will have tendered your Existing Debentures for exchange on the terms and conditions described in the Offering Memorandum and this Letter of Transmittal. You should read the detailed instructions below before completing this Letter of Transmittal.

Note: Signatures must be provided below. Please read the accompanying instructions carefully.

-3-

BOX BELOW TO BE COMPLETED BY  
ALL TENDERING HOLDERS OF EXISTING DEBENTURES

-----  
DESCRIPTION OF EXISTING DEBENTURES TENDERED  
-----

NAMES (S) AND ADDRESS(ES) OF REGISTERED

PRINCIPAL AMOUNT OF  
EXISTING DEBENTURES

Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

HOLDER(S)	CERTIFICATE NUMBER(S) *	TENDERED**
-----	-----	-----
-----	-----	-----
-----	-----	-----
-----	TOTAL	-----

\* Need not be completed by holders who tender by book-entry transfer.  
\*\* Unless otherwise indicated in this column 3, a holder will be deemed to have tendered ALL of the Existing Debentures represented by certificate(s) listed in column 2. (See Instruction 4).

-4-

BOXES BELOW TO BE CHECKED AS APPLICABLE

- [ ] CHECK HERE IF THE CERTIFICATE(S) REPRESENTING YOUR EXISTING DEBENTURES ARE BEING TENDERED WITH THIS LETTER OF TRANSMITTAL.
- [ ] CHECK HERE IF THE CERTIFICATE(S) REPRESENTING YOUR EXISTING DEBENTURES HAVE BEEN LOST, DESTROYED OR STOLEN AND YOU REQUIRE ASSISTANCE IN OBTAINING A NEW CERTIFICATE(S).\*

Certificate Number(s):

-----

Principal Amount(s) Represented:

-----

\* You must contact the Exchange Agent to obtain instructions for replacing lost, destroyed or stolen certificate(s) representing Existing Debentures. (See Instruction 12)

IF DELIVERED BY NOTICE OF GUARANTEED DELIVERY, COMPLETE THE FOLLOWING:

- [ ] CHECK HERE AND ENCLOSE A PHOTOCOPY OF THE NOTICE OF GUARANTEED DELIVERY IF TENDERED EXISTING DEBENTURES ARE BEING DELIVERED UNDER A NOTICE OF GUARANTEED DELIVERY PREVIOUSLY SENT TO THE EXCHANGE AGENT, AND COMPLETE THE FOLLOWING:

Name(s) of Registered Holder(s):

-----

Window Ticket Number (if any):

-----

Date of Execution of Notice of Guaranteed Delivery:

-----

Name of Institution which Guaranteed Delivery:

-----

IF DELIVERED BY BOOK-ENTRY TRANSFER, COMPLETE THE FOLLOWING:

- [ ] CHECK HERE IF TENDERED EXISTING DEBENTURES ARE BEING DELIVERED BY BOOK-ENTRY TRANSFER TO THE EXCHANGE AGENT'S ACCOUNT AT THE DEPOSITORY TRUST COMPANY AND COMPLETE THE FOLLOWING:

Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

Name of Tendering Institution:

-----

Account Number:

-----

Transaction Code Number:

-----

[ ] CHECK HERE IF TENDERED EXISTING DEBENTURES NOT TO BE TENDERED OR NOT EXCHANGED ARE TO BE RETURNED BY CREDITING THE DEPOSITORY TRUST COMPANY ACCOUNT NUMBER INDICATED ABOVE.

-5-

SPECIAL PAYMENT/ISSUANCE INSTRUCTIONS  
(SEE INSTRUCTIONS 1, 5 AND 6)

To be completed ONLY if certificates for Existing Debentures not exchanged and/or New Debentures are to be issued in the name of someone other than the Registered Holder of the Existing Debentures.

[ ] Issue New Debentures to:

[ ] Issue unexchanged Existing Debentures to:

Name(s): -----

Address: -----

-----

Telephone: -----

Tax Identification or Social Security Number (See Instruction 9):

-----

[ ] Credit unexchanged Existing Debentures delivered by book-entry transfer to the following DTC account:

DTC Account

Number: -----

SPECIAL DELIVERY  
INSTRUCTIONS  
(SEE INSTRUCTIONS 1, 5 AND 6)

To be completed ONLY if certificates for Existing Debentures not exchanged and/or New Debentures are to be sent to someone other than the Registered Holder of the Existing Debentures or to the Registered Holder at an address other than that shown below:

[ ] Deliver New Debentures to:

[ ] Deliver unexchanged Existing Debentures to:

Name(s): -----

Address: -----

Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

Telephone: -----

Tax Identification or Social Security Number (See Instruction 9):  
-----

-6-

Ladies and Gentlemen:

Upon the terms and subject to the conditions of the Exchange Offer, as described in the Offering Memorandum and this Letter of Transmittal, I hereby tender to Meridian Bioscience, Inc. ("Meridian") the aggregate principal amount of Existing Debentures described above in the box entitled "Description of Existing Debentures Tendered" in exchange for an equal principal amount of New Debentures.

Subject to and effective upon the acceptance for exchange of all or any portion of the Existing Debentures tendered by this Letter of Transmittal in accordance with the terms and conditions of the Exchange Offer -- including, if the Exchange Offer is extended or amended, the terms and conditions of any extension or amendment -- I hereby sell, assign and transfer to, or upon the order of, Meridian all right, title and interest in and to the Existing Debentures tendered by this Letter of Transmittal. I hereby irrevocably constitute and appoint the Exchange Agent as my agent and attorney-in-fact -- with full knowledge that the Exchange Agent is also acting as the agent of Meridian in connection with the Exchange Offer -- with respect to the tendered Existing Debentures, with full power of substitution, such power of attorney being deemed to be an irrevocable power coupled with an interest, subject only to the right of withdrawal described in the Offering Memorandum, to (1) deliver certificates representing the tendered Existing Debentures to Meridian together with all accompanying evidences of transfer and authenticity to, or upon the order of, Meridian, (2) present certificates representing the tendered Existing Debentures for transfer, and to transfer the tendered Existing Debentures on the books of Meridian, and (3) receive for the account of Meridian all benefits and otherwise exercise all rights of ownership of the tendered Existing Debentures, all in accordance with the terms and conditions of the Exchange Offer.

I hereby represent and warrant that I have full power and authority to tender, sell, assign and transfer the Existing Debentures tendered by this Letter of Transmittal and that, when the tendered Existing Debentures are accepted for exchange, Meridian will acquire good, marketable and unencumbered title to the tendered Existing Debentures, free and clear of all liens, restrictions, charges and encumbrances, and that the tendered Existing Debentures are not subject to any adverse claims or proxies. I will, upon request, execute and deliver any additional documents deemed by Meridian or the Exchange Agent to be necessary or desirable to complete the exchange, sale, assignment and transfer of the Existing Debentures tendered by this Letter of Transmittal. I have read and agree to all of the terms of the Exchange Offer.

The name(s) and address(es) of the Registered Holder(s) -- which term, for purposes of this Letter of Transmittal, includes any participant in The Depository Trust Company's system whose name appears on a security position listing as an owner of Existing Debentures -- are printed above as they appear on the certificate(s) representing the Existing Debentures tendered by this Letter of Transmittal. The certificate number(s) of the Existing Debentures that I wish to tender are indicated in the appropriate boxes above.

Unless I have otherwise indicated by completing the box entitled "Special Payment/ Issuance Instructions" above, I hereby direct that the New Debentures

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

be issued in the name(s) of the undersigned or, in the case of a book-entry transfer of Existing Debentures, that the New Debentures be credited to the account indicated above maintained with The Depository Trust Company. Similarly, unless I have otherwise indicated by completing the box entitled "Special Delivery Instructions," I hereby direct that the New Debentures be delivered to the address shown below my signature.

If I have (1) tendered any Existing Debentures that are not exchanged in the Exchange Offer for any reason or (2) submitted certificates for more Existing Debentures than I wish to tender, unless I have otherwise indicated by completing the boxes entitled "Special Payment/ Issuance Instructions" or "Special Delivery Instructions," I hereby direct that certificates for any Existing Debentures that are not tendered or not exchanged should be issued in the name of the undersigned and delivered to the address shown below my signature or, in the case of a book-entry transfer of Existing Debentures, that Existing Debentures that are not tendered or not exchanged be credited to the account indicated above maintained with The Depository Trust Company, in each case, at Meridian's expense, promptly following the expiration or termination of the Exchange Offer.

I understand that if I decide to tender Existing Debentures, and Meridian accepts all or any part of such Existing Debentures for exchange, this will constitute a binding agreement between me and Meridian with

-7-

respect to the Existing Debentures so accepted for exchange, subject to the terms and conditions set forth in the Offering Memorandum and this Letter of Transmittal.

I also recognize that, under certain circumstances described in the Offering Memorandum under the caption "The Exchange Offer," Meridian may not be required to accept for exchange any Existing Debentures tendered by this Letter of Transmittal.

By tendering Existing Debentures and executing this Letter of Transmittal, or delivering an "agent's message" instead of this Letter of Transmittal, I hereby waive any and all rights to receive any payments, including, without limitation, interest payments with respect to the Existing Debentures beyond the date such Existing Debentures are accepted for exchange, and waive any and all claims that arise out of or are based upon my ownership or acquisition of the Existing Debentures, and agree that Meridian's obligations to me under the New Note indenture and the New Debentures described in the Offering Memorandum supersede and replace in their entirety Meridian's obligations to me under the Existing Note indenture and the Existing Debentures.

Any Existing holder who becomes eligible to receive consideration under the terms of the Exchange Offer will receive New Debentures issued in principal amounts equal to that of the Existing Debentures so tendered and accepted for exchange.

All authority conferred in or agreed to be conferred in this Letter of Transmittal will survive my death or incapacity, and any obligation of mine under this Letter of Transmittal will be binding upon my heirs, executors, administrators, personal representatives, trustees in bankruptcy, legal representatives, successors and assigns. Except as stated in the Offering Memorandum, this tender is irrevocable.

-8-



Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

PLEASE COMPLETE SUBSTITUTE FORM W-9 BELOW  
(SEE INSTRUCTION 9)

SIGNATURE(S) MUST BE GUARANTEED IF REQUIRED BY INSTRUCTION 2

This Letter of Transmittal must be signed by (1) the Registered Holder(s) -- which term, for purposes of this Letter of Transmittal, includes any participant in The Depository Trust Company's system whose name appears on a security position listing as an owner of Existing Debentures -- exactly as the name(s) of the Registered Holder(s) appear(s) on the certificate(s) for the Existing Debentures tendered or on the register of holders maintained by Meridian, or (2) any person(s) authorized to become the Registered Holder(s) by endorsements and documents transmitted with this Letter of Transmittal. If the signature below is by a trustee, executor, administrator, guardian, attorney-in-fact, officer of a corporation or another acting in a similar fiduciary capacity, please set forth the signer's full title. (See Instruction 5).

SIGN HERE

-----  
-----

Signature(s) of Existing Note Holder(s)

Name(s): -----  
(Please Print or Type)

Date: -----, 2003

Capacity: -----

Address: -----  
(Including Zip Code)

Area Code and Telephone Number: -----

Tax Identification or Social Security Number: -----  
(See Instruction 9)

SIGNATURE(S) GUARANTEED  
(SEE INSTRUCTION 2)

Eligible Guarantor Institution: -----

Official Signature: -----

Date: -----, 2003

-9-

SUBSTITUTE FORM W-9

DEPARTMENT OF TREASURY  
INTERNAL REVENUE SERVICE

TO BE COMPLETED BY ALL TENDERING HOLDERS  
(SEE INSTRUCTION 9)

PAYOR'S NAME:  
-----

Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

-----  
SUBSTITUTE  
FORMW-9  
DEPARTMENT OF THE TREASURY  
INTERNAL REVENUE SERVICE

PART 1 -- PLEASE PROVIDE YOUR TIN IN THE BOX AT THE RIGHT AND CERTIFY BY SIGNING AND DATING BELOW. For individuals, this is your Social Security Number (SSN). For sole proprietors, use your Social Security Number or see the Instructions in the enclosed Guidelines. For other entities, use your Employer Identification Number (EIN). If you have applied for, but have not received, a TIN, write "Applied For" in the box at the right, sign and date this certificate and see the enclosed Guidelines. If you do not have a TIN see the enclosed Guidelines on obtaining one.

-----  
TIN:  
Social Security  
Number or Empl  
Identification

PAYOR'S REQUEST  
FOR TAXPAYER  
IDENTIFICATION  
NUMBER ("TIN")  
AND CERTIFICATION

-----  
PART 2 -- CERTIFICATION -- UNDER PENALTIES OF PERJURY, I CERTIFY THAT: (1) the number shown on this form is my correct Taxpayer Identification Number (or I am waiting for a number to be issued to me), (2) either I am exempt from backup withholding, I have not been notified by the IRS that I am subject to backup withholding as a result of a failure to report all interest and dividends, or the IRS has notified me that I am no longer subject to backup withholding, and (3) I am a U.S. person (including a resident alien).  
Signature

-----  
Date:  
-----

-----  
You must cross out Item (2) of the above certification (Part 2) if you have been notified by the IRS that you are subject to backup withholding because of underreporting of interest or dividends on your tax returns and you have not been notified by the IRS that you are no longer subject to backup withholding. The IRS does not require your consent to any provisions of this document other than the certifications required to avoid backup withholding.

Failure to complete and return this Substitute Form W-9 may result in backup withholding of any payments made to you on account of the New Debentures. Please review the enclosed Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9 for additional details.

-10-

INSTRUCTIONS  
FORMING PART OF THE TERMS AND CONDITIONS OF THE EXCHANGE OFFER

1. Delivery of Letter of Transmittal and Certificates; Guaranteed Delivery Procedures. You must complete this Letter of Transmittal if you are a Registered Holder -- which term, for purposes of this Letter of Transmittal, includes any participant in The Depository Trust Company's system whose name appears on a security position listing as an owner of Existing Debentures -- and either (1) you wish to tender the certificates representing your Existing

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

Debentures to the Exchange Agent together with this Letter of Transmittal or (2) you wish to tender your Existing Debentures by book-entry transfer to the Exchange Agent's account at The Depository Trust Company and you elect to submit this Letter of Transmittal to the Exchange Agent instead of an "agent's message." In order to constitute a valid tender of your Existing Debentures, unless you comply with the guaranteed delivery procedures described below, the Exchange Agent must receive the following documents at one of the addresses listed above prior to the expiration date of the Exchange Offer: (1) certificates for the Existing Debentures, in proper form for transfer, or book-entry confirmation of transfer of the Existing Debentures into the Exchange Agent's account at The Depository Trust Company, (2) a properly completed and duly executed Letter of Transmittal, with any required signature guarantees, or, in the case of a book-entry confirmation, an "agent's message" instead of this Letter of Transmittal, and (3) all other documents required by this Letter of Transmittal.

If you are a holder of Existing Debentures and wish to tender your Existing Debentures, but your certificates for Existing Debentures are not immediately available, time will not permit the certificates for the Existing Debentures or other required documents to reach the Exchange Agent before the expiration date of the Exchange Offer, or the procedure for book-entry transfer cannot be completed before the expiration date of the Exchange Offer, you may effect a tender if: (1) the tender is made through an "eligible guarantor institution" (as defined in Instruction 2 below); (2) prior to the expiration date of the Exchange Offer, the Exchange Agent receives from an "eligible guarantor institution" a properly completed and duly executed Notice of Guaranteed Delivery, substantially in the form we have provided, setting forth your name and address and the amount of Existing Debentures you are tendering and stating that the tender is being made by Notice of Guaranteed Delivery; and (3) the Exchange Agent receives within three New York Stock Exchange ("NYSE") trading days after the date of execution of the Notice of Guaranteed Delivery: (a) the certificates for all physically tendered Existing Debentures, in proper form for transfer, or a book-entry confirmation of transfer of the Existing Debentures into the Exchange Agent's account at The Depository Trust Company, as the case may be, (b) a properly completed and duly executed Letter of Transmittal, with any required signature guarantees, or, in the case of a book-entry confirmation, an "agent's message" instead of the Letter of Transmittal, and (c) all other documents required by this Letter of Transmittal. The Notice of Guaranteed Delivery may be sent by overnight courier, hand delivery, registered or certified mail or facsimile transmission and must include a guarantee by an "eligible guarantor institution" in the form set forth in the Notice of Guaranteed Delivery.

The method of delivery of certificates for Existing Debentures, Letters of Transmittal, "agent's messages" and all other required documents is at your election. If you deliver your Existing Debentures by mail, we recommend registered mail, properly insured, with return receipt requested. In all cases, you should allow sufficient time to assure timely delivery. Please send certificates for Existing Debentures, Letters of Transmittal, "agent's messages" or other required documents to the Exchange Agent at the address listed above. Please do not send these documents to Meridian.

Meridian will not accept any alternative, conditional or contingent tenders. Each tendering holder, by execution of this Letter of Transmittal or delivery of an "agent's message" instead of the Letter of Transmittal, waives any right to receive any notice of the acceptance of such tender.

2. Guarantee of Signatures. No signature guarantee on this Letter of Transmittal is required if:

(a) this Letter of Transmittal is signed by the Registered Holder -- which term, for purposes of this Letter of Transmittal, includes any participant in

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

The Depository Trust Company's system whose name appears on a security position listing as an owner of Existing Debentures -- unless such holder(s) have completed either the box entitled "Special Payment/Issuance Instructions" or the box entitled "Special Delivery Instructions" above; or

-11-

(b) the Existing Debentures are tendered for the account of a firm that is an "eligible guarantor institution."

In all other cases, an "eligible guarantor institution" must guarantee the signature(s) on this Letter of Transmittal. (See Instruction 5). An "eligible guarantor institution" (as defined in Rule 17Ad-15 promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) means:

- Banks (as defined in Section 3(a) of the Federal Deposit Insurance Act);
- Brokers, dealers, municipal securities dealers, municipal securities brokers, government securities dealers and government securities brokers (as defined in the Exchange Act);
- Credit unions (as defined in Section 19B(1)(A) of the Federal Reserve Act);
- National securities exchanges, registered securities associations and clearing agencies (as these terms are defined in the Exchange Act); and
- Savings associations (as defined in Section 3(b) of the Federal Deposit Insurance Act).

3. Inadequate Space. If the space provided in the box captioned "Description of Existing Debentures Tendered" is inadequate, the certificate number(s) and/or the principal amount of Existing Debentures and any other required information should be listed on a separate signed schedule attached to this Letter of Transmittal.

4. Partial Tenders and Withdrawal Rights. If you are tendering less than all of the Existing Debentures evidenced by any certificate you are submitting, please fill in the principal amount of Existing Debentures which are to be tendered in column 3 of the box entitled "Description of Existing Debentures Tendered." In that case, unless you have otherwise indicated by completing the box entitled "Special Payment/ Issuance Instructions" or "Special Delivery Instructions," new certificate(s) for the remainder of the Existing Debentures that were evidenced by your old certificate(s) will be sent to the Registered Holder of the Existing Debentures, promptly after the expiration date of the Exchange Offer. The entire principal amount of all Existing Debentures represented by certificates delivered to the Exchange Agent will be deemed to have been tendered unless otherwise indicated.

Except as otherwise provided in this Letter of Transmittal, tenders of Existing Debentures may be withdrawn (i) at any time prior to the expiration date of the Exchange Offer or (ii) from and after December 12, 2003, if Meridian has not accepted the tendered Existing Debentures for exchange by that date. For a withdrawal pursuant to clause (i) to be effective, a written notice of withdrawal must be received by the Exchange Agent prior to the expiration date of the Exchange Offer at the address listed above. Any notice of withdrawal must specify the name of the person who tendered the Existing Debentures to be withdrawn, identify the Existing Debentures to be withdrawn, including the principal amount of the Existing Debentures, and, where certificates representing Existing Debentures have been transmitted, specify the name in which the Existing Debentures are registered, if different from that of the withdrawing holder. If certificates for Existing Debentures have been delivered

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

or otherwise identified to the Exchange Agent, then, prior to the release of the certificates, the withdrawing holder must also submit the serial numbers of the particular certificates to be withdrawn and a signed notice of withdrawal with signatures guaranteed by an "eligible guarantor institution" unless the holder is an "eligible guarantor institution." If Existing Debentures have been tendered using the procedure for book-entry transfer described in the section of the Offering Memorandum entitled "The Exchange Offer -- Book-Entry Transfer," any notice of withdrawal must specify the name and number of the account at The Depository Trust Company to be credited with the withdrawn Existing Debentures and otherwise comply with the procedures of the book-entry transfer facility. All questions as to the validity, form and eligibility, including time of receipt, of withdrawal notices will be determined by Meridian. Any such determination will be final and binding. Any Existing Debentures so withdrawn will be deemed not to have been validly tendered for purposes of the Exchange Offer. Properly withdrawn Existing Debentures may be retendered at any time prior to the expiration date of the Exchange Offer by following one of the procedures described in the section of the Offering Memorandum entitled "The Exchange Offer -- Procedures for Tendering Existing Debentures."

Any Existing Debentures which have been tendered for exchange but which are not exchanged for any reason will be returned to the Registered Holder without cost to that holder promptly after withdrawal, non-acceptance of tender or termination of the Exchange Offer. In the case of Existing Debentures tendered using the

-12-

procedure for book-entry transfer described in the section of the Offering Memorandum entitled "The Exchange Offer -- Book-Entry Transfer," the Existing Debentures will be credited to the tendering holder's account with The Depository Trust Company.

5. Signatures on Letter of Transmittal, Assignments and Endorsements. If this Letter of Transmittal is signed by the Registered Holder(s) of the Existing Debentures tendered hereby, the signature(s) must correspond exactly with the name(s) as written on the face of the certificate(s) without alteration, enlargement or any change whatsoever. If any of the Existing Debentures tendered hereby are registered in the name of two or more joint owners, all such owners must sign this Letter of Transmittal. If any tendered Existing Debentures are registered in different name(s) on several certificates, it will be necessary to complete, sign and submit as many separate Letters of Transmittal as there are different Registered Holders.

When this Letter of Transmittal is signed by the Registered Holder(s) of the Existing Debentures listed and transmitted by this Letter of Transmittal, no endorsement(s) of certificate(s) or separate bond power(s) are required unless New Debentures are to be issued in the name of a person other than the Registered Holder(s). Signatures on certificates or bond powers must be guaranteed by an "eligible guarantor institution."

If a person or persons other than the Registered Holder(s) of Existing Debentures signs the Letter of Transmittal, certificates for the Existing Debentures must be endorsed, or accompanied by appropriate bond powers, signed exactly as the name(s) of the Registered Holder(s) that appear on the certificates for the Existing Debentures. Signatures on certificates or bond powers must be guaranteed by an "eligible guarantor institution."

If you are a trustee, executor, administrator, guardian, attorney-in-fact, officer of a corporation, or act in a similar fiduciary or representative capacity, and wish to sign this Letter of Transmittal or any certificates for Existing Debentures, you must indicate your status when signing. If you are acting in any of these capacities, you must submit proper evidence satisfactory

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

to us of your authority to so act unless we waive this requirement.

6. Special Issuance and Delivery Instructions. If New Debentures are to be issued in the name of a person other than the signer of this Letter of Transmittal, or if New Debentures are to be delivered to someone other than the signer of this Letter of Transmittal or to an address other than that shown above, the boxes entitled "Special Payment/ Issuance Instructions" and/or "Special Delivery Instructions" on this Letter of Transmittal should be completed. Certificates for Existing Debentures not exchanged will be returned by mail or, if tendered by book-entry transfer, by crediting the account indicated above maintained with The Depository Trust Company. (See Instructions 4 and 5).

7. Irregularities. All questions as to the validity, form, eligibility, including time of receipt, and acceptance of Existing Debentures tendered for exchange will be determined by us in our sole discretion. Our determination will be final and binding. We reserve the absolute right to reject any and all tenders of Existing Debentures improperly tendered or not to accept any Existing Debentures. We also reserve the absolute right to waive any defects or irregularities or conditions of the Exchange Offer as to any Existing Debentures either before or after the expiration date of the Exchange Offer -- including the right to waive the ineligibility of any holder who seeks to tender Existing Debentures in the Exchange Offer. Our interpretation of the terms and conditions of the Exchange Offer as to any particular Existing Debentures either before or after the expiration date of the Exchange Offer -- including the terms and conditions of this Letter of Transmittal and the accompanying instructions -- will be final and binding. Unless waived, any defects or irregularities in connection with tenders of Existing Debentures for exchange must be cured within a reasonable period of time, as determined by us. Neither we, the Exchange Agent nor any other person has any duty to give notification of any defect or irregularity with respect to any tender of Existing Debentures for exchange, nor will we have any liability for failure to give such notification.

8. Questions, Requests for Assistance and Additional Copies. All questions regarding the procedures for tendering in the Exchange Offer and requests for assistance in tendering Existing Debentures should be directed to the Exchange Agent at the address or telephone number set forth on the front cover page of this Letter of Transmittal, or to the Information Agent at the address or one of the telephone numbers set forth on the back cover page of the Offering Memorandum. Additional copies of the Offering Memorandum, this Letter of

-13-

Transmittal or the Notice of Guaranteed Delivery may be obtained from the Exchange Agent, the Information Agent or from your broker, dealer, commercial bank, trust company or other nominee.

9. Tax Identification Number. Federal income tax law generally requires that a tendering holder whose Existing Debentures are accepted for exchange must provide the Exchange Agent (as payor) with the holder's correct taxpayer identification number ("TIN") on Substitute Form W-9 above, or otherwise establish a basis for exemption from backup withholding. If the Exchange Agent is not provided with the correct TIN or an adequate basis for exemption, the Internal Revenue Service may subject the holder or other payee to a \$50 penalty. In addition, payments made by the Exchange Agent on account of the New Debentures issued pursuant to the Exchange Offer may be subject to backup withholding as described under "Certain United States Federal Income Tax Considerations" in the Offering Memorandum.

To prevent backup withholding, each tendering holder of Existing Debentures must provide its correct TIN by completing the Substitute Form W-9 set forth

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

above, certifying that the TIN provided is correct (or that such holder is awaiting a TIN) and that (i) the holder is exempt from backup withholding, (ii) the holder has not been notified by the Internal Revenue Service that such holder is subject to backup withholding as a result of a failure to report all interest or dividends, or (iii) the Internal Revenue Service has notified the holder that such holder is no longer subject to backup withholding. If the Existing Debentures are in more than one name or are not in the name of the actual owner, such holder should consult the Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9 for information on which TIN to report. If a holder does not have a TIN, such holder should consult the Guidelines for instructions on obtaining a TIN. If a holder has applied for, but not yet received, a TIN, such holder should write "applied for" in lieu of its TIN in Part 1 of the Substitute Form W-9. Generally, such holder will have 60 days to obtain a TIN and provide it to the Exchange Agent before interest and dividend payments will be subject to backup withholding. For more information see the Guidelines.

Certain holders -- including, among others, corporations, financial institutions and certain foreign persons -- may not be subject to these backup withholding and reporting requirements. These holders should nevertheless complete the Substitute Form W-9 above to avoid possible erroneous backup withholding. A foreign person may qualify as an exempt recipient by submitting a properly completed IRS Form W-8, signed under penalties of perjury, attesting to that holder's exempt status. Please consult the enclosed Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9 for additional guidance on which holders are exempt from backup withholding.

10. Waiver of Conditions. Our obligation to complete the Exchange Offer is subject to the conditions described in the Offering Memorandum under the caption "The Exchange Offer -- Conditions to the Exchange Offer." These conditions are for our benefit only and we may assert them regardless of the circumstances giving rise to any condition. We may also waive any condition, in whole or in part, at any time prior to the expiration date of the Exchange Offer, in our sole discretion. Our failure at any time to exercise any of the foregoing rights will not constitute a waiver of that right and each right is an ongoing right that we may assert at any time.

11. No Conditional Tenders. No alternative, conditional or contingent tenders will be accepted. All tendering holders of Existing Debentures, by execution of this Letter of Transmittal, waive any right to receive notice of the acceptance of Existing Debentures for exchange.

12. Lost, Destroyed or Stolen Certificates. If any certificate(s) representing Existing Debentures have been lost, destroyed or stolen, the holder should check the box above regarding lost, destroyed or stolen certificates and promptly notify the Exchange Agent. The holder will then be instructed as to the steps that must be taken in order to replace the certificate(s). This Letter of Transmittal and related documents cannot be processed until the procedures for replacing lost, destroyed or stolen certificate(s) have been followed.

13. Transfer Taxes. You will not be obligated to pay any transfer taxes in connection with the tender of Existing Debentures in the Exchange Offer unless you instruct us to register New Debentures in the name of, or request that Existing Debentures not exchanged in the Exchange Offer be returned to, a person other than the registered tendering holder. In those cases, you will be responsible for the payment of any applicable transfer tax. If satisfactory evidence of payment of these taxes or an exemption from payment is not submitted with this Letter

Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

of Transmittal, no newly registered Existing Debentures will be issued until such evidence is received by the Exchange Agent.

IMPORTANT: UNLESS YOU COMPLY WITH THE GUARANTEED DELIVERY PROCEDURES DESCRIBED ABOVE, THIS LETTER OF TRANSMITTAL (OR A FACSIMILE OF THIS LETTER OF TRANSMITTAL), OR, IN THE CASE OF EXISTING DEBENTURES TENDERED BY BOOK-ENTRY TRANSFER TO THE EXCHANGE AGENT'S ACCOUNT AT THE DEPOSITORY TRUST COMPANY, AN "AGENT'S MESSAGE" INSTEAD OF THIS LETTER OF TRANSMITTAL, AND ALL OTHER REQUIRED DOCUMENTS MUST BE RECEIVED BY THE EXCHANGE AGENT PRIOR TO THE EXPIRATION DATE OF THE EXCHANGE OFFER.

-15-

NOTICE OF GUARANTEED DELIVERY

MERIDIAN BIOSCIENCE, INC.

OFFER TO EXCHANGE  
5% CONVERTIBLE SUBORDINATED DEBENTURES DUE 2013  
IN PRINCIPAL AMOUNT OF \$16,000,000 FOR EQUAL AMOUNT OF  
OUTSTANDING 7% CONVERTIBLE SUBORDINATED DEBENTURES DUE 2006  
PURSUANT TO THE OFFERING MEMORANDUM  
DATED NOVEMBER 12, 2003

THE EXCHANGE OFFER WILL EXPIRE AT 12:00 MIDNIGHT, EASTERN TIME, ON  
DECEMBER 11, 2003, UNLESS EXTENDED OR EARLIER TERMINATED.

This form or one substantially equivalent hereto must be used to accept the Exchange Offer of Meridian Bioscience, Inc. ("Meridian") made pursuant to the Offering Memorandum, dated November 12, 2003 (the "Offering Memorandum"), and the enclosed Letter of Transmittal (the "Letter of Transmittal") if certificates for Existing Debentures are not immediately available, the procedure for book-entry transfer cannot be completed on a timely basis, or time will not permit all required documents to reach the Exchange Agent prior to the expiration date of the Exchange Offer. Such form may be delivered or transmitted by facsimile transmission, mail or hand delivery to the Exchange Agent as set forth below. Capitalized terms not defined herein are defined in the Offering Memorandum or the Letter of Transmittal.

The Exchange Agent for the Exchange Offer is:

LaSalle Bank, National Association

Personal Delivery:  
135 South LaSalle Street, Suite 1811  
Chicago, IL 60603  
Attention: Corp. Trust Operations

Confirm by Telephone: (312) 904-2450  
Toll-free: (800) 246-5761

Delivery of this Notice of Guaranteed Delivery to an address or facsimile number other than as set forth above will not constitute a valid delivery.

This Notice of Guaranteed Delivery is not to be used to guarantee signatures. If a signature on a Letter of Transmittal is required to be guaranteed by an "eligible guarantor institution" under the instructions thereto, such signature guarantee must appear in the applicable space provided in the signature box in the Letter of Transmittal.



Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

Ladies and Gentlemen:

Upon the terms and conditions set forth in the Offering Memorandum and the accompanying Letter of Transmittal, the undersigned hereby tenders to Meridian the principal amount of Existing Debentures set forth below, pursuant to the guaranteed delivery procedures described in the section of the Offering Memorandum entitled "The Exchange Offer -- Guaranteed Delivery Procedures."

The undersigned understands that tenders of Existing Debentures pursuant to the Exchange Offer may not be withdrawn after the expiration date of the Exchange Offer, except in the limited circumstances described in the Offering Memorandum. Tenders of Existing Debentures may be withdrawn only as provided in the Offering Memorandum.

All authority herein conferred or agreed to be conferred by this Notice of Guaranteed Delivery shall survive the death or incapacity of the undersigned, and every obligation of the undersigned under this Notice of Guaranteed Delivery shall be binding upon the heirs, personal representatives, executors, administrators, successors, assigns, trustees in bankruptcy and other legal representatives of the undersigned.

Principal Amount of Existing Debentures Tendered:	If Existing Debentures will be delivered by book-entry transfer, provide account number
\$	The Depository
	Trust Company: Account Number:

-----  
PLEASE SIGN HERE  
-----

-----  
Signature(s) of Owner(s) or Authorized Signatory

Date:  
-----

Area Code and Telephone Number:  
-----

Must be signed by the holder(s) of Existing Debentures as the name(s) of such holder(s) appear(s) on the certificate(s) for the Existing Debentures or on a security position listing, or by person(s) authorized to become registered holder(s) by endorsement and documents transmitted with this Notice of Guaranteed Delivery. If any signature is by a trustee, executor, administrator, guardian, attorney-in-fact, officer of a corporation or other person acting in a fiduciary or representative capacity, such person must set forth his or her full title below and furnish evidence of his or her authority as provided in the Letter of Transmittal.

-2-

PLEASE PRINT NAME(S) AND ADDRESS(ES)

Name(s) :  
-----

-----  
Capacity:  
-----

-----  
Address(es):  
-----  
-----

-3-

GUARANTEE  
(Not to be used for signature guarantees)

The undersigned, an "eligible guarantor institution" as defined in the Letter of Transmittal, hereby: (a) represents that each holder of Existing Debentures on whose behalf this tender is being made "owns" the Existing Debentures covered hereby within the meaning of Rule 14e-4 under the Securities Exchange Act of 1934, as amended; (b) represents that such tender of Existing Debentures complies with such Rule 14e-4; and (c) guarantees that, within three NYSE trading days from the date of this Notice of Guaranteed Delivery, a properly completed and duly executed Letter of Transmittal (or a facsimile thereof), together with certificates representing the Existing Debentures covered hereby, in proper form for transfer (or confirmation of the book-entry transfer of such Existing Debentures into the Exchange Agent's account at The Depository Trust Company, pursuant to the procedure for book-entry transfer set forth in the Offering Memorandum), and all required documents will be deposited by the undersigned with the Exchange Agent.

The undersigned acknowledges that it must deliver the Letter of Transmittal and Existing Debentures tendered hereby to the Exchange Agent within the time period set forth above and that failure to do so could result in financial loss to the undersigned.

Name of Firm:  
-----

Authorized Signature:  
-----

Name:  
-----

Title:  
-----

(please print)

Address:  
-----

(include zip code)

Area Code and Telephone Number:  
-----

Dated:  
-----

, 2003

-4-

Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

LETTER TO BROKERS, DEALERS, COMMERCIAL BANKS,  
TRUST COMPANIES AND OTHER NOMINEES

MERIDIAN BIOSCIENCE, INC.

OFFER TO EXCHANGE  
5% CONVERTIBLE SUBORDINATED DEBENTURES DUE 2013  
IN PRINCIPAL AMOUNT OF \$16,000,000 FOR EQUAL AMOUNT OF  
OUTSTANDING 7% CONVERTIBLE SUBORDINATED DEBENTURES DUE 2006  
PURSUANT TO THE OFFERING MEMORANDUM,

DATED NOVEMBER 12, 2003

THE EXCHANGE OFFER WILL EXPIRE AT 12:00 MIDNIGHT, EASTERN TIME,  
ON DECEMBER 11, 2003, UNLESS EXTENDED OR EARLIER TERMINATED.

November 12, 2003

To: Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees:

Meridian Bioscience, Inc. is offering to exchange (the "Exchange Offer"), upon and subject to the terms and conditions set forth in the Offering Memorandum, dated November 12, 2003 (the "Offering Memorandum"), and the enclosed Letter of Transmittal (the "Letter of Transmittal"), its 5% Convertible Subordinated Debentures due 2013 in the principal amount of \$16,000,000 for an equal principal amount of its outstanding 7% Convertible Subordinated Debentures due 2006 (the "Existing Debentures").

We are requesting that you contact your clients for whom you hold Existing Debentures regarding the Exchange Offer. For your information and for forwarding to your clients for whom you hold Existing Debentures registered in your name or in the name of your nominee, or who hold Existing Debentures registered in their own names, we are enclosing the following documents:

1. Offering Memorandum, dated November 12, 2003;
2. The Letter of Transmittal for your use and for the information of your clients;
3. A Notice of Guaranteed Delivery to be used to accept the Exchange Offer if certificates for the Existing Debentures are not immediately available, time will not permit all required documents to reach the Exchange Agent prior to the Expiration Date (as defined below), or the procedure for book-entry transfer cannot be completed on a timely basis;
4. A form of letter which may be sent to your clients for whose account you hold Existing Debentures registered in your name or the name of your nominee, with space provided for obtaining such clients' instructions with respect to the Exchange Offer; and
5. Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9.

Your prompt action is requested. The Exchange Offer will expire at 12:00 midnight, Eastern time, on December 11, 2003, unless extended by us (as it may be extended, the "Expiration Date"). The Existing Debentures tendered pursuant to the Exchange Offer may be withdrawn at any time before the Expiration Date or at any time after December 12, 2003 if we have not accepted the tendered Existing Debentures for exchange by that date.

Unless a holder of Existing Debentures complies with the procedures

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

described in the section of the Offering Memorandum entitled "The Exchange Offer -- Guaranteed Delivery Procedures," the holder must do one of the following on or prior to the Expiration Date to participate in the Exchange Offer:

- tender the Existing Debentures by sending the certificates for the Existing Debentures, in proper form for transfer, a properly completed and duly executed Letter of Transmittal, with any required signature guarantees, and all other documents required by the Letter of Transmittal, to the Exchange Agent, at the address set forth on the front cover page of the Letter of Transmittal; or
- tender the Existing Debentures by using the book-entry procedures described in the section of the Offering Memorandum entitled "The Exchange Offer -- Book-Entry Transfer" and transmitting a properly completed and duly executed Letter of Transmittal, with any required signature guarantees, or an "agent's message" (defined below) instead of the Letter of Transmittal, to the Exchange Agent.

In order for a book-entry transfer to constitute a valid tender of Existing Debentures, the Exchange Agent must receive a confirmation of book-entry transfer (a "Book-Entry Confirmation") of the Existing Debentures into the Exchange Agent's account at The Depository Trust Company prior to the Expiration Date. The term "agent's message" means a message, transmitted by The Depository Trust Company and received by the Exchange Agent and forming a part of the Book-Entry Confirmation, which states that The Depository Trust Company has received an express acknowledgment from the tendering holder of Existing Debentures that the holder has received and has agreed to be bound by the Letter of Transmittal.

If a registered holder of Existing Debentures wishes to tender the Existing Debentures in the Exchange Offer, but the certificates for the Existing Debentures are not immediately available, time will not permit the certificates for the Existing Debentures or other required documents to reach the Exchange Agent before the Expiration Date, or the procedure for book-entry transfer cannot be completed before the Expiration Date, a tender of Existing Debentures may be effected by following the Guaranteed Delivery Procedures described in the section of the Offering Memorandum entitled "The Exchange Offer -- Guaranteed Delivery Procedures."

We will, upon request, reimburse brokers, dealers, commercial banks, trust companies and other nominees for reasonable and necessary costs and expenses incurred by them in forwarding the Offering Memorandum and the related documents to the beneficial owners of Existing Debentures held by them as nominee or in a fiduciary capacity. We will pay or cause to be paid all stock transfer taxes applicable to the exchange of Existing Debentures in the Exchange Offer, except as set forth in Instruction 13 of the Letter of Transmittal.

Any inquiries you may have with respect to the Exchange Offer, or requests for additional copies of the enclosed materials, should be directed to the Exchange Agent for the Exchange Offer, at the telephone number or address set forth on the front cover page of the Letter of Transmittal.

MERIDIAN BIOSCIENCE, INC.

Nothing herein or in the enclosed documents shall constitute you or any other person as an agent of Meridian Bioscience, Inc., the Exchange Agent or the Information Agent, or authorize you or any other person to use any document or make any statements on behalf of them with respect to the Exchange Offer, except for statements expressly made in the Offering Memorandum or the Letter of Transmittal.

LETTER TO CLIENTS

MERIDIAN BIOSCIENCE, INC.

OFFER TO EXCHANGE  
5% CONVERTIBLE SUBORDINATED DEBENTURES DUE 2013  
IN PRINCIPAL AMOUNT OF \$16,000,000 FOR EQUAL AMOUNT OF  
OUTSTANDING 7% CONVERTIBLE SUBORDINATED DEBENTURES DUE 2006  
PURSUANT TO THE OFFERING MEMORANDUM  
DATED NOVEMBER 12, 2003

THE EXCHANGE OFFER WILL EXPIRE AT 12:00 MIDNIGHT, EASTERN TIME, ON  
DECEMBER 11, 2003, UNLESS EXTENDED OR EARLIER TERMINATED.

To our clients:

Enclosed for your consideration is an Offering Memorandum, dated November 12, 2003 (the "Offering Memorandum"), and a Letter of Transmittal (the "Letter of Transmittal"), relating to the offer (the "Exchange Offer") of Meridian Bioscience, Inc. ("Meridian") to exchange its 5% Convertible Subordinated Debentures due 2013 in the principal amount of \$16,000,000 for an equal principal amount of its outstanding 7% Convertible Subordinated Debentures due 2006 (the "Existing Debentures"), upon the terms and subject to the conditions set forth in the Offering Memorandum and the Letter of Transmittal.

This material is being forwarded to you as the beneficial owner of the Existing Debentures carried by us in your account but not registered in your name. A tender of such Existing Debentures may only be made by us as the holder of record and pursuant to your instructions.

Accordingly, we request instructions as to whether you wish us to tender on your behalf the Existing Debentures held by us for your account, pursuant to the terms and conditions set forth in the enclosed Offering Memorandum and Letter of Transmittal.

Your instructions should be forwarded to us as promptly as possible in order to permit us to tender the Existing Debentures on your behalf in accordance with the provisions of the Exchange Offer. The Exchange Offer will expire at 12:00 midnight, Eastern time, on December 11, 2003, unless extended by Meridian (as it may be extended, the "Expiration Date"). Any Existing Debentures tendered pursuant to the Exchange Offer may be withdrawn at any time before the Expiration Date or at any time after December 12, 2003 if Meridian has not accepted the tendered Existing Debentures for exchange by that date.

1. The Exchange Offer is for up to \$16,000,000 in principal amount of the Existing Debentures.

2. The Exchange Offer is subject to certain conditions set forth in the section of the Offering Memorandum entitled "The Exchange Offer -- Conditions to the Exchange Offer."

3. Any transfer taxes incident to the transfer of the Existing Debentures from the holder to Meridian will be paid by Meridian, except as otherwise provided in Instruction 13 of the Letter of Transmittal.

4. The Exchange Offer expires at 12:00 midnight, Eastern time, on the Expiration Date, unless extended by Meridian.

PLEASE READ THE OFFERING MEMORANDUM

Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

If you wish to tender your Existing Debentures, please so instruct us by completing, executing and returning to us the instruction form on the last page of this letter. The Letter of Transmittal is furnished to you for information only and may not be used directly by you to tender Existing Debentures.

If we do not receive written instructions in accordance with the procedures presented in the Offering Memorandum and the Letter of Transmittal, we will not tender any of the Existing Debentures on your account. Unless a specific contrary instruction is given in the space provided, your signature(s) hereon shall constitute an instruction to us to tender all the Existing Debentures held by us for your account, upon and subject to terms and conditions set forth in the Offering Memorandum and the Letter of Transmittal.

Please carefully review the enclosed material as you consider the Exchange Offer.

INSTRUCTIONS WITH RESPECT TO THE EXCHANGE OFFER

The undersigned acknowledge(s) receipt of your letter and the enclosed material referred to therein relating to the Exchange Offer made by Meridian with respect to the Existing Debentures. This will instruct you to tender the Existing Debentures held by you for the account of the undersigned, upon and subject to terms and conditions set forth in the Offering Memorandum and the Letter of Transmittal.

Please tender the Existing Debentures held by you for my account as indicated below:

The aggregate face amount of Existing Debentures held by you for the account of the undersigned is (fill in amount):

\$\_\_\_\_\_ of 7% Convertible Subordinated Debentures due 2006.

With respect to the Exchange Offer, the undersigned hereby instructs you (check appropriate box):

[ ] TO TENDER the following Existing Debentures held by you for the account of the undersigned (insert principal amount of Existing Debentures to be tendered (if any)):

\$\_\_\_\_\_ of 7% Convertible Subordinated Debentures due 2006.

[ ] NOT TO TENDER any Existing Debentures held by you for the account of the undersigned.

SIGN HERE

Name of beneficial owner(s) (please print):

-----  
-----

Signature(s):

-----

Address:

-----

Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 424B3

-----  
Telephone Number:  
-----

Taxpayer Identification or  
Social Security Number:  
-----

Date: \_\_\_\_\_, 2003